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“A man who wants the truth becomes a scientist; a man who wants to give free play to his 
subjectivity may become a writer; but what should a man do who wants something in 
between?”  
 
― Robert Musil, The Man Without Qualities 
  
  
 
 
  
ABSTRACT 
Multiple sclerosis (MS) is a chronic, neuroinflammatory disease and one of the leading 
reasons for neurological disability among young people in the Western World. MS patients 
commonly experience neuropsychiatric symptoms including depression and cognitive 
dysfunction. 
The aims of this thesis were to (study I-III) epidemiologically study the occurrence of 
common psychiatric diagnoses and their consequences, such as disability pension (DP) and 
suicide, among MS patients, and (study IV) examine the association between inflammatory 
biomarkers, depression and stressful events in a clinical cohort of MS patients. 
For studies I-III, Swedish national and clinical registers were used to identify patients with 
MS from the 1960s to 2012 (n=10,750- 29,617) and non-MS comparison subjects, as well as 
several covariates including sociodemographic data, disability pension, psychiatric diagnoses, 
prescriptions of psychiatric drugs, and attempted and completed suicide. Statistical analyses 
estimated the adjusted risks for a) having psychiatric diagnoses, b) the risk for being granted 
DP if having a psychiatric diagnosis, c) the prescription patterns of selective serotonin 
reuptake inhibitors (SSRIs), benzodiazepines and sleeping medications in the years around 
DP, and d) the risk for attempted and completed suicide. 
For study IV, 47 patients with MS in a clinical setting were assessed using self-rating scales 
and clinical interviews regarding symptoms and diagnosis of depression, and exposure to 
violence in childhood or adult life. Cerebrospinal fluid (CSF) interleukin (IL)-6 and -8 levels 
were analyzed and compared with results from the psychiatric ratings. 
In study I-III, MS patients were at higher risk for having most psychiatric diagnoses and 
medications compared to non-MS subjects. MS patients with psychiatric diagnoses or 
medications had a higher risk for DP compared to those without. MS patients with DP had a 
higher risk for prescription of SSRIs and benzodiazepines than non-MS subjects with DP. 
MS patients had a nearly doubled risk for both attempted and completed suicide. In study IV, 
higher IL-6 levels were associated with depressive symptoms and exposure to violence in 
adult life, while IL-8 levels were not associated with any investigated parameters. 
We conclude that MS patients are at risk for psychiatric comorbidity, with increased 
rates of serious consequences such as DP and attempted and completed suicide. 
Furthermore, DP is not associated with a decrease in psychiatric drug prescription, as 
in non-MS patients. Also, both depressive symptoms and exposure to violence were 
associated with an inflammatory biomarker in CSF in MS patients, further establishing 
the association between neuroinflammation, psychiatric symptoms and exposure to 
stress.  
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1 BACKGROUND 
 
1.1 MULTIPLE SCLEROSIS 
1.1.1 Introduction 
Multiple sclerosis (MS) is a chronic, autoimmune inflammatory disease of the central 
nervous system (CNS). As such, it can cause a wide variety of neurological symptoms, 
ranging from movement and sensory to cognitive disabilities. MS is described as the leading 
cause of neurological disability among young and middle-aged people in the Western world. 
With onset most commonly in early adult life, MS can have a detrimental impact on several 
aspects of life. 
The main focus of this brief overview of the literature will be on psychiatric aspects of the 
disease, reviewing biological and epidemiological evidence and the association with 
occupational disability. Although this thesis does not focus directly on the areas of cognitive 
dysfunction or fatigue, these areas will be covered for completeness due to their complex 
interplay with depression.  
1.1.2 Epidemiology 
The global mean prevalence of MS is 33/100,000, but with considerable variation[1]. 
Prevalence is highest in North America and Europe, with Sweden being the European 
country with the highest reported prevalence (189/100,000)[1]. A north-south gradient has 
been suggested, and questioned[2], but seems to be confirmed in some later studies, at least in 
the Western hemisphere[3,4]. 
The female to male ratio of MS ranges from 2:1 to 3:1, and it is unclear whether this ratio has 
increased over time[3,4]. Although MS can be diagnosed at any age, the average age of onset 
is 30 years[1]. An approximate 2-5% of patients are diagnosed under the age of 18[5]. 
1.1.3 Pathology 
MS pathology is characterized by an autoimmune inflammatory response targeting myelin, a 
lipoprotein manufactured by oligodendrocytes which normally forms a sheath around axons 
of neurons[6]. The characteristic lesions of demyelination and inflammation (“plaques”) that 
can be observed radiologically and post mortem are often found in a periventricular white 
matter distribution, as well as in the corpus callosum, the optical nerve and the spinal cord. 
Lesions are categorized into active, inactive or chronic active depending on inflammatory 
activity and histological cell content; i.e., the activation of macrophages and CD4+ and CD8+ 
T lymphocytes. Cortical demyelination and general atrophy are often prevalent especially in 
progressive disease stages[7]. Disease progression is mediated by accumulated axon 
degeneration[8]. 
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1.1.4 Etiology 
The etiology of MS is largely unknown, but genetic and environmental risk factors have been 
proposed. More than 100 associated genetic risk variants have been identified[9], and siblings 
to MS patients have a somewhat increased risk for the disease[10]. Vitamin D 
deficiency/sunlight exposure[11], Epstein Barr-virus infection[12] and cigarette smoking[13] 
have all been associated with MS, which could be explained by their respective 
immunomodulating properties. 
1.1.5  Diagnosis and clinical sub-types of MS 
The current criteria for diagnosis of MS, the so-called updated McDonald criteria, consist of 
clinical and laboratory parameters aiming to demonstrate dissemination of CNS lesions in 
time and space[14]. The most commonly used division of MS into sub-types is based on the 
clinical course[15]. Of newly diagnosed patients, 80% suffer from relapsing-remitting MS 
(RRMS)[1], characterized by exacerbations of neurological symptoms followed by complete 
or partial recovery. Of these patients around 90% will in time develop secondary progressive 
MS (SPMS), meaning irreversible and/or progressive disability[16]. About 10% of patients 
have a primary progressive form (PPMS) at disease onset[17]. Rarely diagnosed, progressive-
relapsing MS (PRMS) is characterized by ongoing progression from onset which is 
superimposed by clinical relapses. 
1.1.6 Clinical features 
The symptoms of MS generally correspond to the location of lesions, which means that 
presentation can vary widely. Common onset symptoms include limb weakness, optic 
neuritis, paresthesias or dysesthesias, ataxia, diplopia, facial numbness, vertigo, dysarthria, 
marked fatigue and urinary dysfunction. About 80% initially present a single symptom 
(clinically isolated syndrome, CIS) and thus do not yet meet criteria for MS. The rate of new 
exacerbations seldom exceed 1.5 per year[8]. The clinical course usually evolves over several 
decades, with a median time of 28 years relapsing before patients require at least a cane for 
walking[18]. Cortical signs such as aphasia, apraxia, seizures, dementia and extrapyramidal 
symptoms are more common in progressive disease, as is optic nerve and brain stem 
pathology[8]. 
MS patients’ life expectancy is 5-10 years lower than the general population[19]. Among the 
common causes of death are general consequences of neurological disability such as 
infections and cardiovascular complications[20]. 
 
1.2 PSYCHIATRIC COMORBIDITY IN MS 
Although well known since MS was first described in the 19th century[21], the psychiatric 
symptoms of MS have been little investigated up until the last three decades, following the 
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development of standardized psychiatric diagnostic frameworks and advancements in the 
field of neuropsychology. 
1.2.1 Comorbidities or symptoms? 
There are two conceptually different ways of viewing psychiatric symptoms in MS patients - 
as symptoms of the disease itself, or as symptoms of a comorbid psychiatric disorder. There 
is no consensus on this matter in current literature, and the viewpoint chosen seems to vary 
depending on which symptom/comorbidity is studied, and the setting in which the study is 
performed. 
The concept of comorbidity has several definitions in itself, depending on the environment in 
which the constructs are applied (e.g. clinical care, epidemiological research, or health service 
planning or financing)[22]. Different diseases may be found in the same individual for 
several reasons: chance, selection bias, or by one or more types of causal association[22]. The 
latter may be divided into four models: direct causation, associated risk factors, heterogeneity 
(=independent risk factors), and independence (the presence of diagnostic signs of both 
diseases is actually due to a third, underlying disease)[23]. 
In the MS literature in general, symptoms of a more typical neurological character and those 
which are almost exclusively seen in patients with neurological disease, such as pseudobulbar 
affects (see section 1.2.6) are commonly labeled “neuropsychiatric symptoms”. Conditions 
that are common also in patients without neurological disease, such as depression, and those 
who tend to be associated with psychosocial reactions, e.g. anxiety, are more often labeled 
“comorbidities”. 
1.2.2 Depression 
Depression is the most studied psychiatric condition in MS patients. According to the 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition[24], depression is defined 
as a medical diagnosis under the name major depressive disorder (MDD), and is constituted 
by a combination of depressed mood and/or loss of interest or pleasure, persistent over at 
least two weeks, in combination with cognitive (feelings of worthlessness or guilt, disturbed 
concentration, suicidal thoughts) and/or vegetative (weight loss or gain, 
insomnia/hypersomnia, agitation or retardation, fatigue) symptoms. The estimated prevalence 
in MS patients varies widely depending on the definition of depression, the study sample and 
the methods used, but is according to a meta-analysis around 24% in population-based 
studies[25], around three-fold that of the general population. The one-year incidence in a 
clinical sample was 3-10%[26]. In a German claims data study, 20% of MS patients were 
prescribed an antidepressant medication during a single year[27]. Risk factors for depression 
in MS patients may include lower level of education and being unmarried[26] as well as 
being female[28]. Compared to matched controls from the general population, male MS 
patients have a higher burden of depression and anxiety than females[29]. 
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Depression can have a detrimental impact on the MS disease in several ways. It is, together 
with physical disability, the most important factor in determining MS patients’ quality of 
life[30-32]. It is also associated with a higher rate of hospitalizations[33] and lower adherence 
to disease modifying therapy (DMT)[34]. Some studies have shown an association with an 
early disease course [35], and others with advanced disease[26]. There is also an association 
with relapses[36]. In SPMS patients, e.g. after years of disease, feelings of hopelessness 
become more common[37]. In a cohort of MS patients with depression, symptoms were 
unchanged or only slightly decreased in a four-year interval, suggesting a chronic course[38]. 
MDD is a clinical diagnosis, but various self report scales exist for the purposes of screening, 
symptom severity rating, and assistance in diagnosis. Two screening questions, 
corresponding to the MDD core symptoms of depressed mood and loss of interest, may detect 
depression with reasonable sensitivity and specificity in MS patients[39]. The Beck 
Depression Inventory (BDI)[40]is a well-established 21-item measure, of which both the 
original[41,42] and a 7-item version[43] have been validated for MS patients. The Hospital 
Anxiety and Depression scale (HAD)[44] is designed for depression and anxiety assessment 
in somatic patients, and has also been validated for MS patients[41,45]. A recent comparison 
between several self report measures[46] showed that none of the measures used identified 
depression with adequate accuracy, although the Center for Epidemiologic Studies 
Depression Scale (CES-D)[47] and the widely used Patient Health Questionnaire-9 (PHQ-
9)[48] showed better detection performance using optimal cut-offs, while another 
comparative validation study found that the PHQ-9, HAD and CES-D all performed 
reasonably well[49]. 
There is an overlap between some depressive symptoms and certain common MS-related 
symptoms such as fatigue, insomnia and cognitive dysfunction. This has caused debate 
regarding both the validity of the diagnosis of MDD in MS patients and the conceptualization 
of comorbidity vs inherent neuropsychiatric symptom[50]. Conceptual models of depression 
in MS have tried to incorporate biological signs such as neuroinflammation as well as 
psychosocial factors (i.e. psychological impact of disability, lowered socioeconomic 
status)[51]. Psychosocial factors have been shown to explain 40% of variance in patients’ 
self-reported depression[52]. However, a temporal relationship between MS diagnosis and 
MDD was not present in one public health register study, arguing that it cannot be solely 
explained by a psychological reaction to the diagnosis[53]. MDD episodes are more common 
among MS patients than time-matched controls before the MS diagnosis[53,54], as are SSRI 
prescriptions[55]. Omitting the overlapping somatic symptoms from rating scales for 
depression has been proposed[56], but this concept has also been criticized for missing vital 
components of depressive symptomatology that can actually improve when MS patients are 
treated for depression[57]. Importantly, the clinical phenotype of depression does not seem to 
differ substantially when comparing MS and non-MS MDD patients[58]. 
Several brain imaging studies have shown associations between depression and MS 
morphology; however, results are diverse and sometimes conflicting. In conventional 
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magnetic resonance imaging (MRI) studies, multiple measures of brain pathology such as 
lesion load, lesion distribution and brain atrophy have been shown to be associated with 
depression, and could explain up to 40% of depression variance[59]. Lower hippocampal 
volume has been associated with depression[60], and has also been shown to be associated 
with higher cortisol levels in depressed MS patients[61]. Newer techniques such as diffusion 
tensor imaging (DTI) show that subtle changes in both white and grey matter can be 
associated with depression in MS patients[62], as can various abnormal communications 
within the limbic systems[63]. In functional MRI, individual differences in depression were 
associated with altered regional activity and functional connectivity patterns within the limbic 
system[64]. 
1.2.3 Suicide 
The most important potential consequence of depression is suicide. The literature as a whole 
demonstrates an elevated suicide risk among MS patients; however, estimates range from no 
risk elevation at all[65] to 14 times that of the general population[66]. Adequately powered 
population based register studies show more uniform results with an about doubled suicide 
risk compared to the general population[67-69]. In a large Swedish hospital sample, the 
highest suicide risk was found in the first year following discharge. Of suicides, 58% 
occurred within 5 years after the first admission[68]. The risk for attempted suicide has been 
investigated in only two studies, one of which showed a three-fold risk increase in MS 
patients[70], and one which did not show any elevated risk[71], but the latter was probably 
underpowered (MS patients n=404). Thoughts of death and self-harm in MS patients are 
associated with illness severity, depression, quality of life, male sex, and being 
unmarried[72]. The relationship between disability status and suicide ideation is, however, 
not clear; in one study, depression predicted suicidal ideation, while disability status did 
not[73] and in another, depression mediated the relationship between disability and suicidal 
ideation[74]. In another study, suicidal thoughts were present in 8% of community patients, 
and were more common in patients over 65 years of age and with bladder or bowel 
symptoms, or speaking or swallowing difficulties[75].  
1.2.4 Cognitive dysfunction 
Since pivotal studies in the 1990s revealed that at least 40% of community dwelling MS 
patients suffer from cognitive dysfunction[76,77], a substantial amount of research has been 
dedicated to this field. Cognitive dysfunction is one of the major causes of social and 
occupational impairment among MS patients[78,79]. Cognitive performance may be affected 
years before MS diagnosis[80]. 
The cognitive domains most commonly affected are attention and information processing 
speed, learning and memory, and executive functions. Attention and information processing 
speed is perhaps the most central domain in cognitive dysfunction in MS, and may also 
impact on other aspects of cognition[81]. The most widely used test for assessing information 
processing speed in MS patients is the Symbol-Digit Modalities test (SDMT)[82] which has 
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consistently proved to be a sensitive screening test for cognitive dysfunction in MS 
patients[76,83]. 
Memory seems to be one of the most affected cognitive domains in MS patients[84]. 
Particular difficulties is seen in encoding, rather than recalling[85,86]. As both visuospatial 
and verbal learning is affected, current expert panels’ suggestions for brief screening tests[87] 
suggest that both the California Verbal Learning test, second edition (CVLT-II)[88] and the 
Brief Visuospatial Memory Test – revised (BVMT-R)[89] are administered when screening 
for cognitive dysfunction. Either test takes, like the SDMT, only a few minutes to administer. 
Executive function refers to a complex set of abilities including planning, analysis and 
problem solving, abstract thinking, response inhibition and overall management of cognitive 
resources[84]. The most common test for evaluating executive function is the Wisconsin 
Card Sorting Test (WCST)[90] and, more recent, the Sorting Test[91]. MS patients have been 
shown to have difficulties completing projects and adapting to new situations[92]. Executive 
dysfunction has traditionally been associated with frontal lobe pathology, e.g. lesions[93], but 
the relationship is not at all clear [94] which is consistent with newer evidence of more 
complex cerebral pathways regulating executive function[95,96]. 
The relation between cognitive dysfunction and MS disease sub-types is not entirely clear. 
RRMS and PPMS/SPMS patients have different cognitive profiles[97], and progressive 
subtypes have been shown to be more frequently and seriously impaired[98], but this could 
be mediated by brain lesion load[99] and brain atrophy[100]. Interestingly, in a study of 
patients with a so-called benign course (at least 15 years of disease with a score on the 
Expanded Disability Status Scale (EDSS)[101] ≤3), 45% were cognitively impaired[102]. In 
cross-section studies, there seems to be no connection between duration of illness and 
cognitive dysfunction[76]. Long-term follow-ups, however, have shown significant 
worsening of cognitive dysfunction over time[103,104]. The relation to physical disability is 
also unclear, with some studies leaning towards an association[76,105]. 
The refinement of MRI techniques have coincided with a substantial literature showing 
correlations between MRI indices and cognitive dysfunction, such as regional and total lesion 
load detected by T1 and T2 weighted MRI[106], juxtacortical lesions[107], and regional and 
generalized atrophy[108]. The latter is perhaps the most important cerebral predictor of 
cognitive dysfunction. DTI studies have shown correlation between indices of normal 
appearing brain tissue and cognitive dysfunction[109]. Also, functional MRI studies have 
shown that cerebral adaption to cognitive deficits is possible by increasing activity in other 
brain regions[110]. However, this ability is limited by the extent of brain pathology[111]. 
1.2.5 Fatigue 
Fatigue is the most commonly reported symptom among MS patients[112]. It affects up to 
80% of patients[113] and is for many the most disabling symptom[114]. 
  13 
MS fatigue has been described as “a subjective lack of physical and/or mental energy that is 
perceived by the individual or caregiver to interfere with usual or desired activities”[115]. 
Attempts to define the concept in a medical context has been made[116], emphasizing that it 
is reversible, can impair both motor and cognitive functions, can appear spontaneously or be 
brought on by mental or physical activity, humidity, acute infection and food ingestion. It is 
usually worse in the afternoon. 
Fatigue is more common in progressive forms of MS than in RRMS[117]. Most studies have 
not noticed any differences between the sexes[118].  
Using conventional MRI techniques, lesion load does not seem to be strongly correlated to 
fatigue[119], but DTI shows a possible contribution of grey matter pathology[120]. Both 
global[121] and regional[122] brain atrophy has been associated with fatigue. 
1.2.6 Anxiety and other psychiatric problems 
The literature on anxiety in MS patients is small compared to that on depression, cognitive 
dysfunction and fatigue. Yet, preliminary research, both clinical and epidemiological, has 
shown that anxiety may be as common, if not even more so, than depression in MS 
patients[123,124]. Regarding specific anxiety disorders, the lifetime prevalence of panic 
disorder, obsessive-compulsive disorder and generalized anxiety disorder were shown to be 
three times as common among MS patients than among the general population, while social 
anxiety was less common[124]. A problem might be that anxiety in itself  - in contrast to the 
anxiety disorder diagnoses - is not well defined as a diagnosis, nor well characterized as a 
symptom, in the psychiatric literature[24]. 
Sleeping problems are among the most commonly reported symptoms in MS patients, with 
insomnia having been reported among more than 50%[125]. Sleeping problems are 
associated with other common MS symptoms such as pain, restless legs and fatigue. Poor 
sleep quality is associated with fatigue, depression and anxiety[126]. 
Although less common, an elevated risk has been reported among MS patients also for 
bipolar disorder[53, 127]. An association with psychotic disorders has been demonstrated in 
some studies [128] but not in others[53]. Changes in personality traits have been reported in 
MS suggesting a frontal affection[129]. An increasing body of research on personality traits 
have shown them to mediate the relation between gray matter volume and psychiatric 
symptoms[130], predict quality of life[131], and be related to occupational stress[132]. The 
concept of personality traits should, however, be distinguished from the current psychiatric 
diagnostic concept of personality disorders, the prevalence of which is unknown in MS 
patients. 
In stages of advanced disease, MS patients have increasing rates of conditions with a more 
neuropsychiatric profile such as pseudobulbar affects (pathological laughing and crying)[133] 
and euphoria/apathy[134].  
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1.2.7 MS and stress 
MS patients have been proposed to have alterations in the hypothalamic-pituitary-adrenal axis 
function, the most important stress-response system which is also associated with the innate 
immune response[135]. Stressful life events of various kinds have been associated with the 
appearance of new MR lesions[136] as well as with exacerbations[137]. Coping mechanisms 
were shown to moderate this association[138]. The question whether physical trauma is 
associated with the onset of multiple sclerosis has been controversial, but a qualitative review 
article excluded an association[139]. A recent meta-analysis, however, saw an association 
with MS onset for some types of premorbid trauma in case-control studies, but not in cohort 
studies[140]. MS patients have a higher risk than healthy controls for having experienced 
childhood trauma[141]. This was associated with number of relapses, but not with disability. 
1.2.8 The relationship between depression, cognitive dysfunction and fatigue 
Being in some ways overlapping, but phenomenologically distinct, the concepts of 
depression, cognitive dysfunction and fatigue seem to have a complex relationship in MS 
patients. This has given rise to a diverse and often conflicting body of literature trying to 
establish associations and/or causal connections between two or all three concepts. 
Depression and fatigue have been showed to be highly correlated, even when somatic 
depressive symptoms were excluded[142,143]. Depressed patients have greater fatigue 
symptoms[118] and have notable symptom overlap[144]. Depression is also associated with 
worsening of fatigue symptoms over time[145]. Fatigue may be harder to treat when an 
untreated depression is present[144].  Causality, if it exists, is complex, as depression can 
predict later fatigue and anxiety, while anxiety and fatigue can predict later depression[146]. 
Psychological factors such as a sense of loss of control over one’s environment could be a 
shared underlying component[147,148].  
Early studies of cognitive dysfunction in MS patients did not reveal an association with 
depression[76, 149], but results were perhaps confounded by not controlling for vegetative 
symptoms such as fatigue[81]. Later studies quite consistently showed that depression affects 
information processing and working memory[150-152] as well as executive functions[151]. 
Non-somatic depressive symptoms was the strongest clinical predictor for cognitive 
impairment in one study, in which no association with fatigue was found[153]. This lack of 
association between cognitive dysfunction and fatigue is consistent with the findings of other 
studies[152,154,155]. However, recent findings include fatigue being associated with 
decreased attention and vigilance[156], although the overlap with depressive symptoms may 
not have been considered[157]. 
1.2.9 Comparisons of prevalence with other medical conditions 
MS is a unique disease regarding the combination of its mechanism of inflammation in the 
CNS, onset in young adult life, and chronic and fluctuating course, creating a special profile 
regarding the risk for psychiatric comorbidity which is not wholly comparable to other 
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medical conditions. Furthermore, in order to make adequate comparisons regarding 
prevalence of comorbidities, the same methods should be used in when comparing the 
diseases which preferably means studying them simultaneously, which is rare. However, 
some comparisons can be made. 
Rheumatoid arthritis (RA) is a chronic, often disabling inflammatory disease with increasing 
incidence with age, peaking between ages 40 and 50[158]. It is more common among 
women[158]. As with MS, several new treatments have emerged in the last decade, but in the 
case of RA, these treatments have improved outcomes dramatically for many patients[159]. 
Depression is the most common comorbidity in RA, with a prevalence of more than 15% in 
meta-analyses[160] and 37% using the PHQ-9[161]. Depression is associated with 
disability[161] and lower age[160]. Although much less studied, anxiety was more common 
than among controls and more common than depression in one population-based study on 
chronic arthritis[162]. Suicide risk has not been determined among RA patients, but the risk 
for suicide attempts is increased[163]. 
Systemic lupus erythematosus (SLE) is, like MS, a chronic autoimmune disorder, which can 
among other organs affect the CNS. It commonly has a relapsing-remitting course. It is also 
more common among women, and the most common age of onset is young middle age[164]. 
In a systematic review[165], depression prevalence ranged between 17-75%, with MDD 
diagnosis at 20-47%. However, no register studies were included and the maximum number 
of participants in any study was 326. In most studies, depression was not related to symptom 
severity. The most common neuropsychiatric comorbidity in SLE is perhaps cognitive 
dysfunction[166]. In a direct comparison, a selection of MS patients tested more poorly on 
several cognitive domains than SLE patients, while depression scores were similar[167]. 
Cognitive symptoms were negatively associated with vocational status in both groups. 
Anxiety may afflict up 24% of SLE patients[168]. No estimations of risk for attempted or 
completed suicide risk exist. Suicide ideation was associated with higher symptom burden 
and unemployment[169]. Unlike MS or RA, the literature on SLE generally uses the term 
“neuropsychiatric symptoms” inherent to the disease rather than “comorbidity”. 
 
1.3 CYTOKINES IN MS AND PSYCHIATRIC DISORDERS 
1.3.1 Cytokines in MS 
Cytokines are small proteins vital for cell signaling, especially in the immune response. They 
can be produced by several cell types and act via receptors on receiving cells. Normal 
cytokine levels are low or absent[170]. They are typically produced in small quantities as a 
response to the environment or to signaling, for example through other cytokines. A balance 
is maintained by pro- and anti-inflammatory cytokines[171].  
Cytokines have been implicated in the pathogenesis of MS in several ways[172]. MS patients 
have been treated with interferon-beta (IFN-β) for over twenty years[173], and it is today the 
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first-line treatment of RRMS. On the other hand, treatment with IFN-ϒ can induce 
exacerbations[174]. Only activated T-cells can cross the blood-brain barrier[175]. Activated 
T-helper (Th) cells produce several cytokines; Interleukin(IL)-12, IFN-ϒ and Tumor necrosis 
factor (TNF)-α which induce Th1-type immune (pro-inflammatory) responses, while IL-6 
and IL-10 induce Th2-type (mostly anti-inflammatory) responses. There seems to be an 
imbalance in favor of Th1-mediated cell response in MS, further supporting the notion that 
the disease is an autoimmune one[176]. TNF-α, IFN-ϒ and IL-10 are present in active brain 
lesions[177]. Transgenic animal studies indicate that overexpression of IL-6, IFN- ϒ and 
TNF- α by astrocytes induces demyelination[178]. The interest in cytokines as MS-specific 
biomarkers has waned in later years due to their very general role in the immune response of 
a number of pathological conditions, with the possible exception of CXCL13 in the 
cerebrospinal fluid (CSF)[179]. However, the central position of the IL-6 family in regulating 
the immune response in MS, inducing an anti-inflammatory phenotype in macrophages[180] 
and stimulating Th17-cell differentiation[181], has suggested that blocking the IL-6 pathway 
may limit immune-mediated tissue injury[182].  
Unfortunately, cytokine detection in MS blood or CSF samples varies widely between 
studies[176,183-185]. Most studies have focused on the theoretically most important 
cytokines mentioned above, with varying results. MS patients have been shown to have 
elevated concentrations of both pro- and anti-inflammatory cytokines in blood compared to 
healthy subjects, independent of disease sub-type[186]. However, levels of most of these 
cytokines do not differ in CSF compared to non-MS controls[185] and detection levels of 
many cytokines in CSF are low. 
1.3.2 Cytokines in MS depression, stress, cognitive dysfunction and fatigue 
Outside of the MS field, cytokines has long been of interest in the search for biomarkers for 
depression. Cytokines can induce “sickness behavior”, i.e. behavioral changes that 
correspond to a physiological adaption to inflammation, but in susceptible individuals this has 
been hypothesized to develop into depression[187].  
There is evidence in depressed patients of upregulation of IL-1, IL-2, IL-6 and TNF-α in 
plasma[188,189]. Therapeutical administration of IFN-α, e.g. for hepatitis A, can cause 
depression and anhedonia[190]. Moreover, the depression severity correlates with higher CSF 
levels of IL-6 and lower levels of the serotonin (5-HT) metabolite 5-hydroxyindoleacetic acid 
(5-HIAA)[191], as well as increased L-kynurenine (KYN)[192]. Cytokines, in particular 
IFN-γ, can increase the enzyme indoleamine-2,3-dioxygenase (IDO)[193], shifting the 
precursor amino acid tryptophan away from the 5-HT-synthesizing indolamine pathway to 
the alternate KYN pathway. In two meta-analyses including serum, plasma and CSF samples, 
TNF-α and IL-6 were elevated in depressed subjects compared with control 
subjects[194,195], and also soluble IL-2 receptors[196]. It is unclear whether this 
inflammation precedes, or is caused, by depression[197]. Inflammatory cytokines is also 
linked to suicidal behavior[198]. Patients who had increased serum levels of TNF-α and 
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responded to antidepressant medication had lowered levels after treatment, which was not the 
case for non-responders[199]. 
Being a neuroinflammatory condition with high rates of depression, MS has been suggested 
as an ideal model to study immune-mediated mood disorders[200]. Looking specifically at 
cytokine studies on MS and depression, TNF- α and IFN- ϒ mRNA expression in peripheral 
blood correlates with symptom severity in depressed patients[201]. MS patients who 
responded to antidepressive treatment had significantly lowered levels of serum IFN-γ after 
treatment[202]. Further support for the role of cytokines comes from animal studies. 
Experimental autoimmune encephalomyelitis (EAE) is the most common model of MS. In 
EAE animals there are correlates of depressive behavior even before onset of demyelination. 
This behavior is associated with elevated IL-1β and TNF-α in the hypothalamus and changes 
in the hypothalamic-pituitary-adrenal (HPA) axis[203]. Inflammation did also modulate 
anxiety in EAE mice, which correlated with increased TNF-α levels in the 
hippocampus[204]. 
Regarding MS fatigue, evidence of association with cytokines is inconsistent. While some 
studies fail to establish a correlation[205], others have shown correlation of fatigue scores 
with IFN- ϒ and TNF-α[206], and blood TNF-α mRNA[207]. 
Tying depression and fatigue together, patients with MS and depression have been shown to 
have increased levels of cytokine-producing CD8+ T-cells – but this finding was even 
stronger correlated to fatigue[208]. Also, when comparing fatigued to non-fatigued patients, 
stimulated production of IFN-γ by peripheral CD3+CD4+ T lymphocytes was related to both 
fatigue and co-morbid depression[209]. 
The topic of cytokines in relation to cognitive dysfunction has been, in comparison, little 
studied. When comparing cognitively impaired with cognitively preserved MS patients, the 
rate of IFN-γ-positive CD4+ and CD8+ T-cells showed modest correlation with processing 
speed and working memory but was, unexpectedly, significantly higher among preserved 
patients[210]. Cytokines such as IL-1β, IL-6 and TNF-α have been suggested to play an 
important role in physiological cognitive processes[211]. 
 
1.4 MS AND WORK DISABILITY 
Although the clinical course and symptoms of MS can vary widely, the disease often causes 
severe disability which can affect many aspects of a patient’s life, such as employment status. 
Over 60% of MS patients of working ages are on disability pension (DP)[212]. Patients often 
enter DP only a few years after diagnosis, in the third and fourth decade of life. RRMS 
patients have higher employment rate than patients with progressive disease[213]. Of patients 
still in employment, 34% have long-term sick leaves yearly[212]. Reduced working ability is 
associated with fatigue and neurological disability, as well as with lower education 
level[214], but cognitive dysfunction and fatigue may mediate the effect of disability on 
employment status[215]. 
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MS patients have 15% lower earnings than matched controls, and patients with a sickness 
duration of at least five years have 38% lower earnings[216]. Figures for social benefits were 
33% and 130% higher for MS patients. While the general populations’ income gradually 
increase over life, MS patients’ income decline[217]. Fifteen percent of patients report unmet 
needs regarding employment from the community[218]. 
The risk of being granted DP is doubled if the MS patient suffers a psychiatric co-
morbidity[219]. In one cross-sectional study, mild depression among patients with benign 
MS was associated with a much higher risk of not being employed[220]. Better self-reported 
memory functioning and less social fatigue has been associated with increased working 
hours[221]. 
In Sweden, all adults below the age of 65 with a disease or injury that has led to permanent 
work incapacity can be granted DP[222]. DP, which may be granted for part- or full-time of 
ordinary working hours, covers up to 64% of the lost income up to a limit. Those with no 
previous income get a minimum level. The customary age for old-age pension is 65 years, but 
may be granted from the age of 61 years. The purpose of DP in the Swedish social insurance 
system is to alleviate the mental and physical strain of having to fulfill ordinary work duties 
in order to secure an income[222], but the actual consequences of receiving DP on MS 
patients’ mental and physical health is largely unknown. Being outside the labor market for 
any reason has a negative association with MS patients’ quality of life[223,224]. 
In the general population, study results are conflicting regarding the association of DP on 
mental health[225-227], perhaps due to differences in study methodology. However, when 
systematically reviewed, prospective studies which follow the subjects before, during, and 
after retirement and/or DP rather uniformly suggest better mental health after 
retirement[228]. 
Register studies on the general population have shown increasing rates of psychiatric 
prescriptions in the years leading up to DP pension, and decreasing rates afterwards[229-
231]. When somatic and psychiatric DP diagnoses were looked at separately, patients with 
psychiatric diagnoses, and especially depression, had a steep increase in antidepressant 
prescriptions before DP, and corresponding large decrease after being granted DP. For 
somatic diagnoses, there was a slight increase of antidepressants in the years leading up to 
DP, and more of a plateau-shape after[230, 231]. 
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2 AIMS AND OBJECTIVES 
 
The overall aim of this thesis was to study the comorbidity of psychiatric symptoms and 
disorders in patients with MS, from both a clinical/biological and an epidemiological point of 
view. The study objectives ranged from examining prevalence of psychiatric comorbidity to 
studying its potential consequences – namely DP, suicide attempts, and suicide - as well as 
studying the relationship between stressful events or depression with immune markers in MS 
patients. 
The specific objectives of the studies that compose this thesis were: 
Study 1. To a) study the risk for having psychiatric diagnoses and being prescribed 
psychiatric medications in a nationwide cohort of MS patients compared to non-MS patients, 
and b) study whether psychiatric diagnoses and/or prescriptions were associated with the risk 
for future DP among MS patients. 
Study 2. To study whether the number of years before or after being granted DP was 
associated with being prescribed psychiatric drugs in a sample of MS patients, and to 
compare this with a sample of matched non-MS control subjects who had also been granted 
DP. 
Study 3. To study the risk and risk factors for attempted suicide and completed suicide in a 
nationwide cohort of MS patients, compared to a matched non-MS cohort. 
Study 4. To study the relationship between depression, exposure to violence in childhood and 
adult life, and the cytokines IL-6 and IL-8 in CSF in a clinical cohort of MS patients.  
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3 METHODS 
 
3.1 STUDY SUBJECTS 
3.1.1 Study I and II 
For these two studies, the study population was identified through a combination of data from 
five nationwide registers: 
1. The National Patient Register (NPR), held by the Swedish National Board of Health and 
Welfare (NBHW), starting in the 1960s, with complete information on all in-patient care 
since 1987 and on specialized out-patient care since 2001. Variables registered include 
gender, age, place of residence, county council, hospital/clinic and department; as well as 
main and secondary diagnosis, external cause of injury and poisoning, and procedures, 
according to the version of the International Statistical Classification of Diseases and Related 
Health Problems (ICD) currently in use. The NPR has a high completeness, with missing data 
for main diagnosis at around one percent, and for external causes at three percent[232]. 
2. The Swedish Prescribed Drug Register, which provides information on all prescribed 
drugs, including dosage and Anatomical Therapeutic Chemical (ATC) code[233] dispensed 
at pharmacies in Sweden starting from July 2005[234]. This register is also held by the 
NBHW. 
3. The Swedish Cause of Death Register, which comprises complete data since 1961 on date 
and cause of death, coded according to the current version of the ICD, for all deaths in 
Sweden among inhabitants registered in Sweden[235]. This register is also held by the 
NBHW. 
4. The Longitudinal Integration Database for Health Insurance and Labor Market Studies 
(LISA)[236], a population-based register held by the government agency Statistics Sweden 
and updated annually since 1990. LISA contains various sociodemographic variables 
including source and size of income, occupational status, place of residence, country of birth 
and latest year of immigration. 
5. The Micro Data for Analysis of the Social Insurance (MiDAS) database[237] held by the 
national Social Insurance Agency. This register contains data on diagnosis-specific DP and 
sick leave since 1994, including dates and grade (part or full time). 
The subjects’ unique personal identity numbers assigned to all Swedish residents were used 
to link data from different nationwide Swedish registers. All individuals who were 17-64 
years old, and lived in Sweden, in 2005 were selected from LISA. Presence of MS was 
defined as being hospitalized or receiving specialized care at least once between 2000 and 
2005 with a primary or secondary ICD-10 [238] diagnosis code G35 in the NPR. Thus, 
10,791 MS patients and 5,628,982 non-MS individuals were identified. 
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In study I 65,091 individuals (of which 41 were MS patients) with missing values on place of 
birth and/or educational level at baseline were excluded which granted a cohort consisting of 
10,750 MS-patients, identified through nationwide registers, and 5,553,141 non-MS 
individuals. For the second analysis in this study, only the 4,571 MS patients not on any DP 
in 2005 according to MiDAS were included. 
In study II those MS patients were selected who were granted full-time DP, regardless of 
which diagnosis was stated as the main DP reason, in the years 2000-2012 (n=3,836). For 
every MS patient five matched control subjects were selected according to the procedure 
described under “Analysis”. A flow chart for subject selection is shown in Figure 1. 
 
Figure 1: Study II. Variables from Swedish registers used for identifying subjects and 
analysis variables. 
3.1.2 Study III 
A total of 29,617 MS patients were identified through the NPR and the Swedish MS Register 
(SMSreg)[201] between 1968 and 2012. The SMSreg contains data recorded since 1996 for 
patients who provided written consent with a current nationwide completeness of 
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approximately 80%[201]. Diagnostic accuracy for MS in this register exceeds 95 
percent[239].  
Each MS patient was individually matched with ten Swedish residents without MS diagnosis 
by gender, year of birth and county of residence in Sweden at time for MS diagnosis 
(n=296,164). Matching was performed by the government agency Statistics Sweden. 
Members of the comparison cohort were selected at random from individuals who were alive 
at the time of MS diagnosis in the matched patients. For two of the MS patients only six and 
eight matched controls were available. 
3.1.3 Study IV 
During the study recruiting period of May 2012 to June 2014, all consecutive RRMS patients 
at the MS outpatient clinic at the Karolinska University Hospital, Solna who met the 
following criteria were asked to participate in the study: 1. A recent CSF examination from 
clinical practice, allowing for an interview session within 90 days of sampling. 2. Being 18-
55 years of age. 3. Recent (≤2 years) MS diagnosis, or a current switch in drug treatment 
regime due to relapse and/or side effects. 4. No known main somatic or psychiatric diagnosis 
besides MS. 5. No current psychiatric or psychotropic medication, including glucocorticoids. 
The MS clinic serves an uptake area that includes the central-northern part of Stockholm 
County corresponding to about 40% of the entire population. 
In total, forty-seven subjects who met the criteria and gave informed consent were included in 
the study. A flow chart for subject selection is shown in Figure 2. 
 
Figure 2. Study IV. Study recruitment flow chart. RRMS = Relapsing remitting multiple 
sclerosis, CSF = cerebrospinal fluid, SSRIs = Selective serotonin reuptake inhibitors, TCAs 
= tricyclic antidepressants.  
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3.2 OUTCOME VARIABLES AND COVARIATES 
3.2.1 Study I and II 
Information for 2005 was obtained from LISA regarding age-groups (17-34, 35-44, 45-54, 
55-64), sex, educational level (compulsory school (≤9 years), high school (10-12 years), 
university (≥13 years), country of birth (Sweden, the other Nordic countries, other EU 25, all 
other countries), and type of living area (based on the H-region classification scheme [240] 
and divided into the following three categories: larger cities (H1-H2), medium-sized (H3-H4) 
municipalities or smaller municipalities (H5-H6)). 
For study I, psychiatric comorbidity was identified using the ICD-10 codes F00-F99, here 
organized into nine categories: developmental and organic disorders (F00-09, F70-F89), 
disorders related to substance use (F10–F19), schizophrenia and non-affective psychoses 
(F20-29), bipolar disorder (F31), depressive disorders (F32-F33), affective disorders (F30-39, 
including bipolar disorder and depressive disorder), neurotic and somatoform disorders (F40-
F42, F44-F49), stress-related mental disorders (F43), behavioral disorders (F50–F59, F90–
99), and personality disorders (F60–F69). 
Psychiatric medication was defined as a dispensed prescription for a drug with the ATC 
codes N03-N07 at least once between July and December 2005. The codes were organized 
into nine different groups according to pharmacological class and/or clinical use: selective 
serotonin reuptake inhibitors (SSRIs; N06AB), tricyclic antidepressants (TCAs; N06AA), 
other antidepressants (N06AG02, N06AX), first generation antipsychotics (FGA; N05AA-
N05AD, N05AF), second and third generation antipsychotics (SGA); N05AE, N05AH0, 
N05AX), benzodiazepines (N03AE01, N05BA, N05CD), short-acting sleeping agents 
(N05CF), lithium (N05AN01), and alcohol dependence drugs (N07BB). Anti-convulsants 
and central stimulants were considered but not included as their use in MS patients is 
primarily for non-psychiatric indications. 
In study II the Swedish Prescribed Drug Register was used to obtain information on the 
number of MS patients and non-MS controls with at least one dispensed prescription of 
SSRIs, benzodiazepines, or short acting sleeping agents in 2006. 
3.2.2 Study III 
Attempted suicide was defined as being treated as a hospital inpatient or outpatient for some 
form of self-harm that had been recorded as attempted suicide using ICD diagnostic and 
accident codes (ICD-8 and -9 950-959, ICD-10 X60-X84). 
Suicide as the cause of death was identified through the Cause of Death Register. Completed 
suicide was defined as the same ICD codes as for attempted suicide stated as main or 
contributory cause of death. Deaths with undetermined intent were not included as this could 
possibly overestimate actual rates[241].  
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A measure of educational level was constructed from census data from Statistics Sweden 
(from 1960 onwards), with categories for compulsory school or less, upper secondary, higher 
education, and no educational data available, using the highest recorded level. Dates of death 
and emigration for the entire study period were obtained using the Total Population 
Register[242], which is held by the Swedish Tax Agency and contains current data on 
residents in Sweden regarding such variables as place of residence, family ties, and date and 
place of births and deaths. Linkage between data sources was possible using the subjects’ 
personal identity numbers. 
3.2.3 Study IV 
During a single session, participants were subject to two semi-structured clinical interviews 
conducted by a trained psychiatrist. The MINI International Neuropsychiatric Interview 
(M.I.N.I.) version 6.0.0.b[243], uses DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition)[244] criteria to screen for and clinically validate psychiatric 
diagnoses, including MDD. The Karolinska Interpersonal Violence Scale (KIVS) [245] 
includes four subscales, each ranging from 0-5, measuring exposure to/used interpersonal 
violence as a child (6–14 years old) or adult (15 years of age or older). Violence exposure 
ranges from occasional, low-grade violence (1) up to repeated, serious battering or harm (5). 
The KIVS has a good interrater reliability[245].   
The subjects also filled out the Montgomery-Åsberg Depression Rating Scale, self-report 
version (MADRS-S)[246], which is a nine item questionnaire for rating of depressive 
symptoms according to the DSM criteria for MDD. In order not to confound depressive 
symptoms with common MS-related symptoms such as fatigue or sleeping problems, the five 
cognitive items in the MADRS-S scale (covering the symptoms depressed mood, anxiety, 
pessimism, loss of interest and suicidality) were separated for analysis. Disability was rated at 
the time of CSF sampling with the Expanded Disability Status Scale (EDSS)[101]. 
Foror the laboratory analysis, CSF samples were collected through lumbar puncture using 
Sprotte® spinal needles. The CSF was collected in plastic tubes and centrifuged at 2442 rcf 
for 10 minutes. The supernatant was aliquoted and frozen at -70 oC within three hours of 
sampling. 
Cytokines IL-6 and IL-8 were analyzed from previously unthawed CSF supernatants using 
ELISA kits from R&D systems® (Quantikine® ELISA; MN, USA) according to the 
manufacturer’s protocol. Briefly, standards were reconstituted and serially diluted. Undiluted 
CSF samples, standards and negative controls were added to 96 well pre coated plates in 
duplicates after prior addition of assay diluent in equal quantity to all wells.  After incubation, 
wells were thrice rinsed with wash buffer, decanted and blotted against clean paper towels. 
Interleukin conjugates were added, plates were covered with adhesive strips and left to 
incubate. The wash step was repeated as described above. Substrate solution was added and 
plates were kept protected from light at room temperature for color development, which was 
then abrogated by adding stop solution. Plates were read using a microplate reader 
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(Spectramax® plus 384, Molecular devices, CA, USA) set to 450 nm. Results were acquired 
and analyzed using SoftMax Pro (version 6.2.1, Molecular devices, CA, USA). 
 
3.3 STATISTICAL ANALYSIS 
3.3.1 Study I 
First, descriptive analyses were performed to explore the distribution of the baseline 
covariates among MS patients and non-MS individuals, respectively. Second, logistic 
regression was used to calculate odds ratios (OR) with 95% confidence intervals (CI) for the 
outcomes psychiatric in- and out-patient care (2001-2005) and psychiatric drug prescriptions 
(July-December 2005), for MS-patients compared to non-MS individuals. The analyses were 
adjusted for age group, sex, educational level, country of birth, and type of living area.  
Third, among the 4,571 MS patients not on DP in 2005, survival analyses were performed 
with psychiatric diagnoses and medication as exposures, and disability pension as the 
outcome. The cohort members were followed from 2006 through 2010, or the year the 
individual turned 65, emigrated, died, or was granted old age pension or DP, whichever 
occurred first. In each analysis, the reference group included all subjects without the exposure 
tested (i.e. included subjects with all other diagnosis groups and/or medications). Hazard 
ratios (HR) with 95% confidence intervals (CI) were estimated by proportional hazards 
models. The analyses were adjusted for age group, sex, educational level, country of birth, 
and type of living area. The assumption of proportional hazards was tested and met using 
log/(-log) plots. Each diagnosis group and prescribed drug class was analyzed separately 
throughout the study, not taking into account any co-occurrence of other diagnoses or drugs 
in the subjects. 
Fourth, two-way interactions between age/sex and the exposure variable were introduced in 
both regression and survival models to evaluate the fit of the models. These interactions were 
either deemed non-significant, or did only affect the results marginally. Correction for 
multiple comparisons was performed using the Holm-Bonferroni method[247]. 
3.3.2 Study II 
Patients and controls were matched by year of DP and then by socio-demographic variables 
from the LISA database for 2005; sex, age, type of living area, education level, family 
situation, having children <18 years at home, and country of birth. Variables were organized 
into categories for sex, age group (17–34, 35–44, 45–54, 55–65 years), educational level 
(lower education <12 years or higher education ≥12 years), country of birth (Sweden or other 
country), family situation (married/cohabitant or single), having children <18 years living at 
home (yes/no), and type of living area (large, medium or smaller municipalities according to 
the H classification). A possible MS diagnosis after 2006 was not an exclusion criteria for 
being selected as a control subject. 
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Propensity scores were generated in a logistic regression analysis with MS (yes/no) as the 
dependent variable, and socio-demographic variables (sex, age, type of living area, education 
level, family situation, having children <18 years at home, and country of birth) as covariates. 
The model was evaluated with a Hosmer-Lemeshow test with p>0.05. An 8 to 1 digit Greedy 
matching algorithm was performed to match MS patients with non-MS controls. Covariate 
balance was assessed by the standardized difference method for categorical variables[248]. 
An absolute standardized difference below 10% indicates that no meaningful covariance 
imbalance was present[249], and after matching the values ranged between 0-1.5%. 
In order to perform a cross-sectional study with 2006 being the study year (the year data on 
prescribed dispensed psychiatric drugs was measured), the MS patients and non-MS controls 
were categorized by year of full-time DP into seven study groups: 2000-01, 2002-03, 2004-
05, 2006, 2007-08, 2009-10, and 2011-12, respectively. 
After control matching, descriptive analyses were performed to explore the distribution of the 
socio-demographic covariates among the MS patients. Second, adjusted odds ratios (OR) 
with 95% confidence intervals (CI), were calculated for MS patients and non-MS controls (in 
separate analyses) with those being granted DP in 2006 as the reference group, to determine 
risk for being prescribed the three classes of psychiatric drugs in 2006. The study groups 
were analyzed separately among both MS patients and controls. The three drug classes were 
analyzed separately, without taking into account any co-occurrence of other drugs. 
Third, adjusted OR with 95% CIs were calculated for MS patients compared to non-MS 
controls regarding risk for prescription of the respective psychiatric drugs using General 
Estimating Equations (GEEs) with an exchangeable correlation matrix[250]. GEEs were 
performed due to clustering introduced by the matching procedure, allowing comparison of 
MS patients and controls within each of the seven study groups. Two-way interactions 
between covariates and the exposure variable were introduced in all analyses to evaluate the 
fit of the models, all of which were statistically non-significant (p>0.05). 
3.3.3 Study III 
Separate Cox regression analyses were performed for attempted and completed suicide with 
attained age as the underlying time scale. The reference group was the unexposed (non-MS) 
group. Subjects were followed from first recorded MS diagnosis (and the same time-point for 
matched comparators) and ending at attempted suicide or completed suicide, emigration, 
death, or study end in 2012, whichever occurred first. HR with 95% confidence intervals CI 
were estimated for crude analyses, and also adjusted for sex, residential place at entry, year of 
entry and highest attained education level. Analyses were also stratified by sex, education, 
year of study entry, and duration after study entry. Separate analyses for MS and non-MS 
cohorts were also performed using a dichotomous variable for education (≤14 years versus 
>14 years). Interaction between MS and sex was tested and found non-significant. 
In the analysis for attempted suicide 453 MS patients and 3,557 non-MS comparators were 
excluded because of attempted suicide before entry. Among non-MS comparators, 4,456 
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subjects were also excluded as they were matched to a subject with MS who was excluded 
due to attempted suicide before entry. A sensitivity analysis was performed in which subjects 
who attempted suicide before entry were not excluded from the analysis and included in an 
adjusted model. The proportional hazards assumption was tested and met for all strata. 
3.3.4 Study IV 
First, unadjusted as well as partial (adjusted for sex and age) two-tailed nonparametric 
correlation analyses were performed on IL-6 and IL-8, respectively, and age, EDSS score, the 
MADRS-S cognitive score, MADRS-S total score, the KIVS exposure to violence as a child 
score, and the KIVS exposure to violence as an adult score. Median values for IL-6 and IL-8 
were compared between men and women, and between subjects with and without MDD 
diagnosis, using non-parametric tests.  
Second, multiple regression analyses were performed with IL-6 and IL-8, respectively, as 
dependent variables, with age, sex, MDD diagnosis, EDSS score, and the KIVS score for 
exposure to violence as a child or the KIVS score for exposure to violence as an adult, as 
independent variables. Three patients had IL-6 values under the detection level; these were 
replaced with values 50% below the lowest values in the sample. Non-normal variables were 
transformed through square root transformation, or, if this did not yield a normal distribution, 
Blom transformation[175]. Interaction variables for sex vs. exposure to violence and 
depression were sequentially tested and excluded from the models. The fit of the models was 
confirmed through plotting of residuals. In an additional analysis, MDD diagnosis was 
replaced by the cognitive score from the MADRS-S. Potential mediation effects in the 
models were explored with the PROCESS procedure[251] in SPSS (v23.0, IBM Corp.), 
which was the program used for all statistical analyses. For sensitivity, all regressions which 
included MADRS-S cognitive score were rerun with the total MADRS-S score for 
comparison. 
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4 RESULTS 
 
4.1 STUDY I 
Compared to non-MS subjects in this study, the MS patients were generally older, with a 
mean age of 47 vs 41 years, and more often female, 71% vs 49%. DP was clearly more 
common among MS patients, 61% compared to 10% among non-MS subjects. A larger 
proportion of MS patients were born in Sweden, 91% compared to 86%. Other socio-
demographic data did not differ substantially. 
In Table 1, numbers and percentages of individuals with a psychiatric diagnosis or 
medication are shown for MS patients and non-MS subjects, respectively. It also shows the 
results of the logistic regression analysis presented as adjusted ORs. Ten percent of MS 
patients had received a psychiatric diagnosis, compared to 5.7% of non-MS individuals (OR 
1.82 (95% CI 1.71-1.94)). Depressive disorder was the most common diagnosis in both 
groups; 4.4% of MS patients and 1.7% of the non-MS individuals, respectively (OR 2.41 
(95% CI 2.22-2.64)). All psychiatric diagnoses were overrepresented among MS patients, 
except for personality disorders and substance abuse for which rates were approximately 
equal.  
Thirty-five percent of MS patients had been prescribed a psychiatric drug compared to ten 
percent of non-MS subjects (OR 3.72 (95% CI 3.57-3.88)). Twenty-five percent of the MS 
patients had been prescribed an antidepressant, most commonly SSRIs (17%), compared to 
6.5% of the non-MS individuals, (OR 3.64 (95% CI 3.48-3.80)). Eleven percent of the MS 
patients had been prescribed benzodiazepines and 13 percent sleeping agents, while the 
proportions among the non-MS individuals where three and four percent, respectively (ORs 
3.39 (95% CI 3.19- 3.61) and 2.70 (95% CI 2.55-2.86)). Medication for alcohol dependence 
was the only drug group less prescribed to MS patients (OR 0.59 (95% CI 0.35-1.00)). 
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The results from the survival analysis are shown in Table 2. MS patients with any psychiatric 
diagnosis had a higher HR for DP than MS patients without a diagnosis; HR 1.83 (95% CI 
1.53-2.18). The diagnosis group with the highest HR for DP was personality disorders; HR 
5.42 (95% CI 2.98-9.83). MS patients with a depressive disorder diagnosis had a doubled HR 
for DP, HR 1.95 (95% CI 1.54-2.47). HRs were elevated in all diagnostic groups except for 
bipolar disorder. 
Table 1. Study I. Psychiatric diagnoses and medications in multiple sclerosis (MS) patients and non-MS 
individuals; absolute numbers, percentages and adjusted odds ratios (ORs) with 95% confidence intervals (CI) 
 MS (n=10,750) Non-MS (n=5,553,141)  
Diagnoses n (%) n (%) OR a (95%CI)a 
Developmental, organic disorders 148 (1.4) 17,778 (0.3) 4.66 (3.96-5.49)* 
Substance abuse 162 (1.5) 99,474 (1.8) 0.94 (0.81-1.10)  
Psychotic disorders 82 (0.8) 31,728 (0.6) 1.25 (1.01-1.56)  
Depressive disorders 471 (4.4) 95,275 (1.7) 2.41 (2.22-2.64)* 
Bipolar disorder 51 (0.5) 12,072 (0.2) 1.73 (1.31-2.27)* 
Affective disorders 542 (5.0) 109,969 (2.0) 2.37 (2.18-2.59)* 
Neurotic, somatoform disorders 303 (2.8) 88,768 (1.6) 1.67 (1.49-1.88)* 
Stress-related disorder 170 (1.6) 52,244 (0.9) 1.65 (1.42-1.92)* 
Behavioral disorders 85 (0.8) 32,492 (0.6) 1.68 (1.36-2.08)* 
Personality disorders 42 (0.4) 22,088 (0.4) 0.98 (0.72-1.33)  
Any psychiatric diagnosis 1074 (10.0) 317,493 (5.7) 1.82 (1.71-1.94)* 
Prescribed dispensed medication 
SSRIs 1793 (16.7) 252,027 (4.5) 3.24 (3.08-3,41)* 
TCAs 591 (5.5) 48,405 (0.9) 4.59 (4.22-5.00)* 
Other antidepressants 575 (5.3) 95,879 (1.7) 2.55 (2.34-2.78)* 
Any antidepressant 2685 (25.0) 363,592 (6.5) 3.64 (3.48-3.80)* 
FGA 112 (1.0) 36,626 (0.7) 1.25 (1.04-1.51)  
SGA 116 (1.1) 32,307 (0.6) 1.74 (1.45-2.09)* 
Any antipsychotic 214 (2.0) 62,075 (1.0) 1.53 (1.33-1.75)* 
Benzodiazepines 1134 (10.5) 139,490 (2.5) 3.39 (3.19-3.61)* 
Sleeping agents 1324 (12.3) 199,339 (3.6) 2.70  (2.55-2.86)* 
Lithium 38 (0.4) 11,383 (0.2) 1.29 (0.94-1.77)  
Drugs for alcohol dependance 14 (0.1) 11,716 (0.2) 0.59 (0.35-1.00) 
Any psychiatric drug 3801 (35.4) 558,725 (10.1) 3.72 (3.57-3.88)* 
aadjusted for age, sex, education level, country of birth, and type of living area, *= significant after Bonferroni-
Holm correction for multiple comparisons. SSRI=Selective Serotonin Reuptake Inhibitors, TCA=Tricyclic 
Antidepressants, FGA = First generation Antipsychotics, SGA = Second generation Antipsychotics 
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MS patients with a psychiatric drug prescription of any kind had a higher HR for DP, HR 
2.09 (95% CI 1.84-2.33) than MS patients without a prescription. The drug group with the 
highest HR was antipsychotics, HR 2.56 (95% CI 1.48-4.44). Those prescribed SSRIs, the 
most common group, had a doubled HR for DP, HR 2.15 (95% CI 1.85-2.49). All separate 
drug groups were associated with an elevated risk for DP. 
Table 2: Study I. The hazard ratio (HR) with 95% confidence intervals (CI) for being granted disability pension during a 
five-year follow up (2006-2010) in multiple sclerosis (MS) patients not on disability pension in 2005, n=4750. 
Diagnoses Events/patients (%) Adjusted HR (95% CI) 
Developmental, organic 
disorders 14/24 (0.5) 3.59 (2.11-6.11)* 
Substance abuse 19/40 (0.9) 2.20 (1.39-3.47)* 
Psychotic disorders 3/11 (0.2) 1.06 (0.34-3.29) 
Depressive disorders 75/161 (3.6) 1.95 (1.54-2.47)* 
Bipolar disorder 3/10 (0.2) 0.99 (0.32-3.10) 
Affective disorders 77/172(3.8)  1.85 (1.47-2.33)* 
Neurotic, somatoform disorders 46/113 (2.5) 1.72 (1.28-2.31)* 
Stress-related disorders 30/63 (1.4) 2.03 (1.41-2.93)* 
Behavioral disorders 9/30 (0.7) 1.23 (0.64-2.37) 
Personality disorders 11/12 (0.3) 5.42 (2.98-9.83)* 
Any psychiatric diagnosis 144/342 (7.6) 1.83 (1.53-2.18)* 
Prescribed dispensed medication    
SSRIs 207/415 (9.2) 2.15 (1.85-2.49)* 
TCAs 61/123 (2.7) 2.04 (1.58-2.63)* 
Other antidepressants 74/155 (3.4) 2.02 (1.60-2.56)* 
Any antidepressant 309/632 (14.0) 2.23 (1.96-2.54)* 
FGA 8/15 (0.3) 2.48 (1.23-4.99) 
SGA 6/13 (0.3) 2.37 (1.06-5.30) 
Any antipsychotic 13/26 (0.6) 2.56 (1.48-4.44)* 
Benzodiazepines 74/168 (3.7) 1.77 (1.40-2.24)* 
Sleeping agents 138/320 (7.1) 1.73 (1.45-2.07)* 
Lithium 3/9 (0.2) 1.11 (0.36-3.44) 
Drugs for alcohol dependance 1/2 (0.0) 1.30 (0.89-1.89) 
Any psychiatric drug 403/900 (19.9) 2.09 (1.84-2.33)* 
aadjusted for age, sex, education level, country of birth and type of living area *= significant after Bonferroni-Holm correction for 
multiple comparisons. SSRI=Selective Serotonin Reuptake Inhibitors, TCA=Tricyclic Antidepressants, FGA = First generation 
Antipsychotics, SGA = Second generation Antipsychotics 
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4.2 STUDY II 
In the descriptive analysis the expected socio-demographic differences between the study 
groups were found. The MS patients granted DP earlier were older, less often had children 
living at home, and had a lower educational level than MS patients granted DP later in the 
study period (i.e., 2011/12). The number of patients in each group declined with later years of 
DP, as some reached the age of 65 and were thus not eligible for DP, and partly due to the 
inclusion criteria of the study (i.e., patients with a known MS diagnosis before 2006). The by 
far most common DP diagnoses among non-MS controls were mental disorders (ICD-10 
codes: F00-99, 35.9%) and musculoskeletal disorders (ICD-10 codes: M00-99, 29.2%). 
In the logistic regression analyses (Figure 3), MS patients and controls who had not yet been 
granted DP had approximately similar or lower ORs for psychiatric drug prescription than 
individuals that recently had been granted DP (in 2006) within their respective populations 
(i.e., patients and controls). ORs for all types of psychiatric drugs were lowest among those 
that were to be granted DP in 5-6 years from the reference year 2006 (i.e., study group 
2011/12). 
However, among MS patients who in 2006 had been on DP for 1 year or more, the ORs for 
being prescribed benzodiazepines were substantially higher, especially for those on DP since 
5-6 years (study group 2000/01) (OR 1.73; 95% CI 1.16-2.57). This was not the case among 
the non-MS controls, where ORs were roughly equal to the reference group. 
Regarding SSRIs, the ORs were lower among the non-MS controls who had been granted DP 
5-6 years earlier (OR 0.78; 95% CI 0.68-0.89), which was not the case for the corresponding 
MS patients. For SSRIs, as well as for sleeping agents, ORs did not differ substantially 
between MS patients on DP for several years compared to patients recently granted DP (i.e., 
in 2006). 
In the GEE analyses (Figure 4), the risk for being prescribed SSRIs for MS patients, 
compared with non-MS controls, was not elevated among those not yet on DP, regardless of 
the number of years until DP. However, MS patients who had been on DP for 3-4 and 5-6 
years, respectively, had higher risks for being prescribed SSRIs (for the 5-6 years group: OR 
1.76; 95% CI 1.44-2.15) compared to non-MS controls. Regarding benzodiazepines, MS 
patients with 5-6 years until DP had a substantially lower risks than controls (OR 0.53; 95% 
CI 0.30-0.96), while the risks among those already on DP was roughly equal between patients 
and controls. There were no significant differences in the risks regarding sleeping agents 
between MS patients and non-MS controls.  
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Figure 3. Study II. Risk for psychiatric drug prescription by year from disability pension. Odds ratios (OR) for MS patients and non-MS controls for being prescribed psychiatric drugs, by number of years 
before and after disability pension (DP) (=year 0). ORs are adjusted for sex, age, type of living area, education level, family situation, having children <18 years at home, and country of birth. 
 
Figure 4. Study II. Risk for psychiatric drug prescription by year from disability pension – MS patients vs controls. Odds ratios (OR) for MS patients compared to non-MS controls for being prescribed 
psychiatric drugs - as the dependent variable in a General Estimating Equation analysis. Adjusted for sex, age, type of living area, family situation, having children <18 years at home, and country of birth. 
By number of years before and after disability pension (DP) (=year 0). 
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4.3 STUDY III 
During follow-up, 423 individuals who attempted suicide and 114 who completed suicide 
were found among MS patients, with incidence rates (IR) of 116.5 and 30.31 per 100,000 
person years. The corresponding IR among the non-MS cohort were 50.8 and 16.68. 
Mean age and standard deviation for attempted suicide was 46.3 (±0.60) years among MS 
patients, and 49.6 (±0.35) years for non-MS comparators. Mean age for completed suicide 
was 51.8 (±1.13) years among MS patients, and 56.7 (±0.55) years for non-MS comparators. 
Thirty-seven percent of the suicide attempts in the MS cohort occurred within three years 
after study entry, 57% within 5 years, and 87% within 15 years. Twenty-nine percent of the 
completed suicides in the MS cohort occurred within three years after study entry, 53% 
within 5 years, and 86% within 15 years. While 64% of non-MS comparators with completed 
suicide used a violent method (not self-poisoning), the corresponding proportion was less 
than 53% for MS patients.  
In Table 3, results for the whole study population (MS and non-MS combined) are shown 
with and without adjustments for covariates. In the whole study population, women were at 
higher risk for attempted suicide compared to men, while men were at higher risk for 
completed suicide. Higher education was associated with a reduction in the risk of attempted 
suicide compared with those who participated in upper secondary education, and to a lesser 
extent, so was compulsory school or lower. Higher education was associated with a reduction 
in the risk of completed suicide compared with those who participated in upper secondary 
education, but not compulsory school or lower. Compared to the non-MS group, MS patients 
had a more than doubled risk for attempted suicide, and an 80% risk increase for completed 
suicide, after adjustment for covariates. 
Table 4 shows associations of MS, with non-MS comparators as reference, stratified by 
covariates (e.g. in the stratum of women, women with MS are compared with women who do 
not have MS). Both male and female MS patients had a more than doubled adjusted risk for 
attempted suicide compared with the non-MS group. The adjusted risk for completed suicide 
was more than doubled for women with MS and about 70% increased for men with MS. MS 
was associated with an increased risk of both attempted and completed suicide across 
educational levels. The risk of attempted suicide associated with MS was elevated compared 
with non-MS comparators regardless of decade of study entry. Risk for completed suicide 
was elevated for all decades except for the 1990s, where HRs were not statistically 
significant. 
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Table 3. Study III. -Hazard ratios (HR) and 95% confidence intervals (CI) for attempted and completed suicide 
           Attempted Suicide Completed Suicide 
 Unadjusted HR (95% CI) a Adjusted HR (95% CI) b Unadjusted HR (95% CI) a Adjusted HR (95% CI)b 
Overall     
Non-MS Reference Reference Reference Reference 
MS 2.09 (1.88-2.32) 2.14 (1.92-2.37) 1.76 (1.44-2.14) 1.85 (1.52-2.26) 
Sex      
Men Reference Reference Reference Reference 
Women 1.29 (1.19-1.41) 1.29 (1.19-1.40) 0.37 (0.32-0.42) 0.38 (0.33-0.43) 
Year of entry     
1968-1980 Reference Reference Reference Reference 
1981-1990 0.89 (0.80-0.99) 0.87 (0.78-0.97) 0.66 (0.56-0.78) 0.67 (0.56-0.80) 
1991-2000 0.97 (0.87-1.08) 0.83 (0.74-0.93) 0.53 (0.44-0.65) 0.54 (0.44-0.66) 
2001-2012 0.67 (0.60-0.74) 0.56 (0.50-0.62) 0.28 (0.22-0.34) 0.27 (0.22-0.34) 
Education      
Compulsory school or less 0.73 (0.67-0.80) 0.69 (0.63-0.76) 0.97 (0.84-1.14) 0.84 (0.72-0.98) 
Upper secondary Reference Reference Reference Reference 
Higher education 0.61 (0.55-0.68) 0.62 (0.55-0.69) 0.69 (0.56-0.84) 0.74 (0.60-0.91) 
No educational data 0.23 (0.18-0.29) 0.19 (0.15-0.24) 0.69 (0.53-0.90) 0.45 (0.34-0.59) 
a The variable indication exposure status (MS, non-MS) added to all unadjusted models. bAdjusted for sex, year of entry, education and region of residence at entry 
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Table 4. Study III. Hazard ratios (HR) and 95% confidence intervals (CI) for attempted and completed suicide, stratified by sex, year of entry and education. Reference category is non-MS 
group. 
 Attempted Suicide Completed Suicide 
  Unadjusted HR (95% CI) Adjusted HR (95% CI) a Unadjusted HR (95% CI) Adjusted HR (95% CI) a 
 
Overall 2.09 (1.88-2.32) 2.14 (1.92-2.37) 1.76 (1.44-2,14) 1.85 (1.52-2.26) 
  Sex       
    Men 1.97 (1.61-2.40) 2.01 (1.65-2.45) 1.64 (1.26-2.14) 1.73 (1.32-2.25) 
    Women 2.13 (1.89-2.41) 2.19 (1.94-2.48) 1.96 (1.46-2.64) 2.05 (1.52-2.75) 
  Year of entry       
    68-80 2.06 (1.68-2.52) 2.18 (1.78-2.67) 2.06 (1.53-2.76) 2.14 (1.59-2.87) 
    81-90 2.53 (2.07-3.09) 2.58 (2.11-3.16) 1.92 (1.32-2.80) 1.96 (1.35-2.86) 
    91-00 2.03 (1.63-2.54) 2.02 (1.62-2.52) 0.99 (0.55-1.78) 0.99 (0.55-1.79) 
    01-12 1.85 (1.50-2.28) 1.86 (1.51-2.30) 1.98 (1.20-3.29) 1.98 (1.19-3.28) 
  Education       
   Compulsory school or less 1.85 (1.53-2.24) 1.87 (1.55-2.25) 1.36 (0.96-1.92) 1.43 (1.01-2.03) 
   Upper secondary 2.40 (2.08-2.78) 2.45 (2.12-2.84) 2.00 (1.47-2.73) 2.08 (1.53-2.84) 
   Higher education 1.80 (1.38-2.34) 1.85 (1.42-2.41) 2.16 (1.34-3.49) 2.34 (1.45-3.78) 
   No educational data 2.14 (1.09-4.19) 2.18 (1.11-4.29) 2.03 (1.04-3.99) 2.12 (1.09-4.16) 
aAdjusted for sex, year of entry, education and region of residence at entry 
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The results were similar in the sensitivity analysis in which subjects who attempted suicide 
before entry were not excluded from the analysis (data not shown). When stratified by 
duration after study entry, risk for attempted suicide was highest after >20 years among MS 
patients compared to the non-MS group, while risk for completed suicide was highest in the 
first five years. Despite some variation in risk of completed and attempted suicide in MS 
patients by disease duration, interaction testing did not identify statistically significant effect 
modification by duration (data not shown). 
In a supplementary analysis, having >14 years of education (corresponding to the category of 
higher education) was associated with a lower risk for attempted suicide among both MS and 
non-MS groups compared to subjects with lower education. When the same analysis was 
performed for completed suicide, non-MS subjects with >14 years of education were shown 
to have a lower risk for completed suicide compared with subjects with lower education, 
while MS patients did not. In a sensitivity analysis was performed only on subjects entering 
the study after 1987, results were similar (data not shown). 
4.4 STUDY IV 
Subject characteristics are shown in Table 5. In general, the subjects were recently diagnosed 
with MS, without current active treatment, and had low EDSS and MADRS scores. Six 
subjects (13%) were diagnosed with MDD.  
Table 5. Study IV. Cohort characteristics. Values are means with standard deviations if not otherwise stated. 
Female (%) n= 34 (66)       
Age 35 (8)       
Years since MS diagnosis 2.0 (3.1)       
EDSS score 2.1 (1.1)       
MADRS-S cognitive subscale score 4.4 (4.6)       
Current major depression n = 6       
Current treatment for MS n = 16       
KIVS exposure to violence as child score 0.67 (0.94)      
KIVS exposure to violence as adult score 0.72 (1.1)       
IL-6 (pg/ml) 5.3 (9.7)       
IL-8 (pg/ml) 45.0 (14.1)      
        
EDSS = Expanded Disability Status Scale; MADRS-S = Montgomery-Asberg Depression Rating Scale, Self Report version; KIVS = 
Karolinska Interpersonal Violence Scale; IL = Interleukin  
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Median cytokine levels did not differ significantly between men and women or between 
depressed/non-depressed patients. Subjects with and without current treatment were also 
compared regarding cytokine levels and MADRS-S scores, without significant differences. 
Correlations between cytokine levels and covariates are shown in Table 6. IL-6 correlated 
significantly with both total and cognitive MADRS-S scores, and with the KIVS score for 
exposure to violence as an adult. Levels of IL-8 did not show any significant correlations 
with other measurements. 
Table 6. Study IV. Raw and adjusted correlation coefficients between cytokine levels and covariates, shown as Spearman's ρ with 
two-tailed p-values. 
           
  IL-6       IL-8         
  Unadjusted p Adjusteda p Unadjusted p Adjusteda p   
Age 0.05 0.76 0.44 0.77 -0.12 0.42 -0.12 0.43   
EDSS 0.13 0.38 0.14 0.37 0.09 0.56 0.11 0.47   
MADRS-S 
cognitive 0.38 0.011* 0.35 0.017* -0.15 0.32  - 0.14 0.37   
MADRS-S total 0.41 0.005* 0.41 0.006* -.091 0.55 -0.90 0.56   
KIVS exposure 
to violence as a 
child  0.14 0.34 0.18 0.23 0.14 0.35 0.11 0.49   
” as an adult  0.33 0.025* 0.35 0.010* 0.12 0.93  - 0.006 0.97   
           
a adjusted for age and sex          
*significant at p<0.05          
EDSS = Expanded Disability Status Scale; MADRS-S = Montgomery-Asberg Depression Rating Scale, Self Report version; 
KIVS = Karolinska Interpersonal Violence Scale, exposure to violence; IL = Interleukin    
 
Also, exposure to violence as an adult correlated significantly with MADRS-S cognitive 
score, and with MADRS-S total score when adjusted for sex and age. EDSS score correlated 
significantly with raw and unadjusted MADRS-S total score, and with the adjusted MADRS-
S cognitive score. 
Results from the multiple regressions are shown in Tables 7a and 7b. In the analysis 
including MDD diagnosis, exposure to violence as an adult was significantly associated with 
IL-6 levels, while exposure to childhood violence and MDD diagnosis was not (MDD t=0.32, 
p=0.75). However, when MDD was replaced with MADRS-S cognitive score, exposure to 
adult violence only showed a trend towards significance (p=0.06). MADRS-S cognitive score 
was not significantly associated with IL-6 levels (t=1.47, p=0.15) in the analysis. The 
MADRS-S cognitive score did not have a significant mediating effect on the relation between 
KIVS scores and IL-6. Interaction variables were not significant in the models. In contrast, 
levels of IL-8 did not yield any significant associations in the regression analyses. 
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The sensitivity analyses where MADRS-S cognitive score were replaced with MADRS-S 
total score in the regressions yielded marginally different results and no changes in 
significance.  
Table 7a. Study IV. Results from multiple regressions with a) IL-6 and b) IL-8 as dependent variables and exposure to violence as 
independent variable. Adjusted for major depression diagnosis (yes/no), KIVS scores, age, sex, and EDSS score. 
        
 IL-6  IL-8     
 t p t p    
Exposure to 
violence as a 
child 1.30 0.20 0.26 0.80    
" as an adult 2.43 0.019 -0.47 0.64    
EDSS = Expanded Disability Status Scale; Self Report version; KIVS = Karolinska Interpersonal Violence 
Scale, exposure to violence; IL = Interleukin    
Table 7b. Study IV. Results from multiple regressions with a) IL-6 and b) IL-8 as dependent variables and exposure to violence as 
independent variable. Adjusted for MADRS-S cognitive symptoms, KIVS scores, age, sex, and EDSS score. 
        
 IL-6  IL-8     
 t p t p    
Exposure to 
violence as a 
child 1.06 0.30 0.61 0.55    
" as an adult 1.88 0.060 0.13 0.90    
EDSS = Expanded Disability Status Scale; MADRS-S = Montgomery-Asberg Depression Rating Scale, Self Report version; KIVS 
= Karolinska Interpersonal Violence Scale, exposure to violence; IL = Interleukin    
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5 DISCUSSION 
 
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Register studies 
Although the wealth of data available in Swedish national epidemiological and clinical 
registers brings many opportunities for research, there are also several considerations to be 
made. Observational studies, as opposed to experimental studies, can disclose statistically 
significant associations between the parameters studied but not causal relationships. Spurious 
associations may be made, regardless of the strength of the association. Thus, all results must 
be interpreted with caution. Furthermore, various types of bias may influence both the 
internal and external validity of the findings. 
5.1.1.1 Selection bias 
When the sampling of study subjects is influenced by an unknown factor associated with both 
the exposure and the outcome studied, selection bias has occurred. Studies I-III rely on the 
NPR, and study III also on the SMSreg, for the selection of MS patients. First, only 
specialized in- and out-patient care is recorded in the NPR and not care given in general 
practice/by family physicians. This means that there can be a bias towards patients with more 
severe MS in the study sample. Although it is assumed here that the absolute majority of MS 
patients in Sweden had at least one appointment with a neurologist during the years 2000-
2005, patients with less disability may not seek care or only seek primary care. 
In study III, patients were included from 1968 onwards. In earlier years coverage in the NPR 
was not complete and only in-patient care was recorded, and the latter brings further bias 
towards more severe disease. Furthermore, earlier versions of the ICD were used which are 
not always directly translatable to current versions. Also, the syndrome diagnosis of MS has 
evolved during the years[14] and earlier patients may have had a more obvious symptom 
presentation and severe disease in the lack of laboratory findings. Taking this into 
consideration, results from study III were also stratified by decade of diagnosis. 
National coverage in the SMSreg is estimated at 80%, which means 20% of patients have not 
given consent or are not available for recruitment. Hypothetical reasons for this with potential 
bias could be not seeking specialized neurological care (i.e. less severe disease, or the 
opposite - palliative care), not being able to give informed consent (due to dementia or 
neuropsychiatric symptoms), or declining inclusion because of depression/fatigue. 
Importantly, selection bias can also lead to surveillance bias, which means that observation 
for one condition increases the likelihood of detecting another, which has great implications 
when studying comorbidity. Comparisons between risks for psychiatric diagnoses in study I, 
for example, are most likely biased by this, and by lack of primary care data.  
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Finally, another form of selection bias may be differences in “loss to follow-up” in cohort 
studies, meaning for example that a different proportion of MS patients than comparison 
subjects may have died or moved abroad in study III, or that MS patients with psychiatric 
comorbidity may have died in a greater proportion in the survival analysis in study I. 
5.1.1.2 Misclassification bias 
Misclassification bias is a type of information bias, i.e. that a measurement error introduces 
bias. If this error is systematic across the studied groups, the studied effect becomes smaller. 
If not, bias is introduced. The most likely source of misclassification bias in studies I-III are 
the ICD diagnoses. Regarding MS diagnosis, the accuracy in the SMSreg is high[239], while 
the NPR generally has an acceptable degree of diagnostic accuracy[252] although MS has not 
been examined specifically. Regarding the psychiatric diagnoses, very few have been 
validated in the NPR, with varying but mostly acceptable results[253-255]. Notably, 
depressive disorders and anxiety diagnoses have not been validated. Also, self-harm with 
non-suicidal intent can also be misclassified as a suicide attempt[256], and this classification 
has not been validated in the NPR either. Deaths with undetermined intent were not included 
in order to increase validity in study III. 
A known MS diagnosis could also lead to less reporting of psychiatric diagnosis (i.e. the 
physician sees depression as a phenomenon of the MS disease and does not record a separate 
diagnosis, or does not bother to register secondary diagnoses at all). Psychiatric diagnoses 
among MS patients are probably underreported in this study, which is supported by the 
observation that the corresponding figures for pharmacological treatment in study I are 
generally higher. 
For validation of public health records psychiatric diagnoses among MS patients, a 
combination of diagnostic data and pharmacological prescriptions has been used in some 
studies to increase validity[257]. This approach was not used in study I, where instead 
diagnoses and pharmacological data were analyzed separately. 
Also, education level was used as a covariate in studies I-III, with up to 5% of subjects with 
missing data. These subjects may, for example, have immigrated to Sweden. A small 
percentage of subjects with missing baseline data were excluded in study I, which could have 
introduced a selection bias as being born outside of Sweden was somewhat less common 
among MS patients. 
5.1.1.3 Confounding and mediation 
A confounder is a factor associated with both the exposure and the outcome in a relationship, 
while a mediator lies on the causal pathway between exposure and outcome. In order to 
prevent confounding, a number of sociodemographic covariates were adjusted for in the 
analyses I-III, and closely matched controls were used as comparison cohort in studies II and 
III.  
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The most important mediator of interest regarding most of the outcomes studied in studies I-
III is probably physical disability status, which we did not have information on – although, as 
repeatedly stated in the Introduction section of this thesis, the association between disability 
and psychiatric comorbidity in MS is still not wholly clear. Additionally, this data would 
have been of limited use in the comparisons with non-MS subjects used in these studies, as 
they by definition could not be assessed with MS-specific disability measures (most 
commonly the EDSS).  
5.1.1.4 Validity of the chosen outcomes 
In study I, being granted DP was chosen as a measure of impact of disability. Although, as 
discussed in the Introduction, being outside the labor market is often associated with physical 
disability, it is by no means directly translatable, and should not be interpreted as such. Also, 
no clinical studies on the specific characteristics of MS patients who are granted DP exist. In 
study II, only subjects with full-time DP were selected for comparison. As being granted DP 
is often a gradual process in Sweden, with patients going from sickness absence to partial to 
fulltime DP, this might have diluted the value of this patient selection variable. 
In studies I and II prescriptions of pharmacological data are used as a proxy for psychiatric 
morbidity. An advantage of this measure is that misclassification issues related to registered 
diagnoses discussed above do not arise; however, the studied drugs may be used for several 
disorders (e.g. SSRIs for both anxiety and depression) and may also be used for other 
purposes than psychiatric symptoms/disorders. SSRIs are also used to treat pathological 
laughing and crying in MS patients[133], something that affects only a minority of patients 
with advanced disease. Benzodiazepines are also a last line choice for treating spasticity[258], 
a symptom which could reduce work capacity in MS patients. 
We compared the ratio of patients being prescribed psychiatric drugs as a binary measure 
instead of using the continual measure of, for example, Defined Daily Dosages (DDDs). In 
regard to the size of the study sample, this leaves the analysis less sensitive to outliers (i.e., 
large consumers of benzodiazepines and sleeping agents). It could also be argued that a 
dichotomous category of presence/absence of prescribed psychiatric drugs has a different and 
perhaps more accurate construct validity in measuring psychiatric morbidity on a population 
basis than measuring DDDs, as even singular prescriptions signify an intent to treat 
psychiatric morbidity. MS patients are quite sensitive to side effects from psychiatric 
medication which could lead to a higher number of interrupted treatments. 
5.1.1.5 Statistical conclusion validity 
A type II error means not detecting an association in a test although it is present, and the 
concept is closely connected to that of statistical power. As they are based on registers with 
approximately nationwide coverage, studies I-III are well powered statistically which is 
necessary for detection of rare outcomes. Even so, some of the outcomes measured in study I 
(such as personality disorder diagnoses among MS patients not on DP) were only detected in 
a small number of patients, which means CI are wide and that the conclusions that can be 
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drawn from these observations are limited. In study II, OR were wide and overlapping 
between the different study groups; however, the trends were fairly clear. Suicide is, 
thankfully, a relatively rare outcome among both MS patients and the general population, but 
this also means that the stratification of data in study III brings lower statistical power. 
A type I error means detecting a statistically significant association which is not there, and 
this is closely related to the level of alpha chosen for the test - typically 0.05, which roughly 
translates to a 5% risk of finding a false association. Repeated measurements, and an 
increasing number of covariates tested, increase the risk for a type I error, and in study I this 
was adjusted for with a Bonferroni-Holm correction of the alpha value. 
5.1.1.6 External validity 
These studies have the strength of being based on national, high quality registers with in most 
cases very high completeness. However, as these studies are based solely on data from 
Sweden, the generalizability to other populations could be questioned. Genetic and 
geographical differences are known among MS patients worldwide. Treatment regimes and 
health care systems vary between countries. Especially psychiatric diagnostic traditions and 
prescriptions patterns show wide differences internationally (see for example [196, 259]). As 
national health policies change, data may also not be valid over time. 
Sweden has a well-developed health insurance system, which may not be readily comparable 
to many other countries. The cross-section design in study II may have been sensitive to 
yearly trends in being granted DP, which could be influenced by contemporary agendas in 
national politics. On the other hand, the method has the advantage of not being sensitive to 
trends in pharmacological prescriptions.   
5.1.2 Clinical study 
5.1.2.1 Selection and misclassification bias 
The subjects in this study were selected according to several criteria and do not represent a 
natural sample of MS patients. MS diagnosis and disability score was clinically verified. 
Several measures of depression were applied in order to limit the risk for misclassification 
and subjectivity in the diagnosis. There is always a risk for recall bias regarding historical 
data, as for exposure to violence in this study, and there is the risk that, for example, current 
depression influences this recall bias. 
As described in the introduction, CSF detection and levels of cytokines vary widely between 
studies, and the accuracy and reliability of sampling within or between MS subjects is little 
studied. We cannot say how large the sampling error is in this study, or if it is influenced by 
e.g. cytokine levels, and thereby introducing bias. The sampling in this study was not 
standardized regarding e.g. food intake or time of day, which increases the uncertainty. 
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5.1.2.2 Confounding and mediation 
The analysis in this study was adjusted for age, sex, and disability status, which could be 
significant confounders. Depressive symptoms were investigated as a mediator in this study 
but not found statistically significant; however, this could be a type II error. 
5.1.2.3 Validity of chosen exposures and outcomes 
IL-6 and IL-8 were chosen as immune markers due a combination of properties: well 
established roles in the innate immune response, a repeatedly proven association with 
psychiatric symptomology (especially IL-6) including suicidality and exposure to adversity, 
and a decent detectability in previous studies on MS patients.  
In this study we chose several measures of depression, of which the semi-structured, 
clinician-rated interview is considered the gold standard. The MADRS-S is also a well-
established measure of self-rated depression with the advantage that it closely follows the 
DSM criteria for MDD. To avoid collinearity we primarily analyzed only cognitive self-rated 
symptoms of MDD which also pointed out some differences in the results compared to when 
all symptoms were included. 
Exposure to violence is a type of adversity which has not been investigated previously in MS 
patients. We do not know if or how exposure to interpersonal violence, especially of the low-
grade type most common in this study, differs from other kinds of stress regarding the 
association with depression and IL-6. 
5.1.2.4 Statistical conclusion validity 
This study was probably underpowered regarding performing a logistic regression analysis 
with all covariates included. An option would be to perform a backwards regression, which 
would exclude non-significant variables such as age and sex, thus increasing significance. 
This could, however, decrease the validity of the analysis. The number of patients with MDD 
diagnosis in the sample was unexpectedly low considering previous research. However, the 
association between IL-6, depressive symptoms and especially exposure to violence in adult 
life was rather clear throughout the study. 
5.1.2.5 External validity 
This study was performed on a highly selected sample of MS patients, with low levels of self-
rated depression and MDD diagnoses, short disease duration, and low disability scores. 
Although this is a well-characterized sample, and the newly diagnosed group of MS patients 
is clinically relevant to study, we cannot determine the generalizability of the results 
regarding MS patients as a whole. The findings regarding IL-6 are, however, supported by 
the existing literature on non-MS patients. 
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5.2 IMPLICATIONS OF RESULTS 
 
5.2.1 An elevated risk for psychiatric diagnoses and medications 
To our knowledge, this is the first comprehensive mapping of all types of psychiatric 
diagnoses and drug classes in MS patients. Depressive disorder was, as expected, the most 
common psychiatric diagnosis among both MS patients and non-MS individuals of working 
age. The 4.4% of MS patients who had been diagnosed with depression during the five years 
studied is a rather low proportion compared most studies[25], but as discussed in section 
5.1.1.1, diagnoses from primary care are not included in this study. Furthermore, most 
previous estimates of prevalence of psychiatric diagnoses are based on survey or clinical 
studies, which seem to lead to higher estimates. The exclusion of patients over 65 years of 
age is another possible contributing factor. The risk for bipolar disorder was nearly doubled 
in MS patients compared to non-MS individuals, but the prevalence of 0.5% was lower than 
in other studies[127, 260]. The risk for obtaining a psychotic disorder diagnosis was not 
statistically significant in MS patients with a 0.8% prevalence, in line with the only previous 
register study on this topic [22]. 
In study I, 35% of all MS patients were prescribed a psychiatric medication during the six 
months observed, which was a high number compared to non-MS individuals. The most 
common drug class in the study, SSRIs, was prescribed to 17% of MS patients which 
suggests a high prevalence of depressive disorder and anxiety disorders. Of note is that 
depression has been suggested to be generally underdiagnosed and undertreated in MS 
patients[261, 262], which indicates that the prescription rates would perhaps be even higher if 
MS patients were to receive adequate antidepressant treatment. The tripled risk for 
benzodiazepine prescriptions seen here should be considered problematic, since there is a 
well-known risk for unwanted side effects and dependence, and this drug class not being 
recommended at all in modern clinical guidelines for anxiety disorders[263]. 
Together, these results suggest that analysis of drug prescription data can be used as a proxy 
for psychiatric comorbidity by itself or in combination with diagnostic data, and that an 
elevated risk for almost all kinds of psychiatric comorbidity among MS patients is apparent. 
5.2.2 Psychiatric comorbidities increase the risk for disability pension 
In the survival analysis of study I, psychiatric diagnoses and medications were generally 
associated with a substantially higher HR for DP among MS patients. Depressive disorders 
were the diagnoses associated with the highest absolute number of patients being granted DP, 
further supporting the notion of the detrimental consequences of this comorbidity. It is, 
however, not possible to establish whether this is due to a causative effect of depression, or if 
the elevated rate of depressive diagnoses is due to a psychosocial reaction to an increased 
general disability which in itself eventually leads to DP. Considering the high costs for the 
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individual and for society that is associated with being granted DP, this should be considered 
a priority in future research. 
Although few in absolute numbers, personality disorders were the diagnoses with the highest 
HR for DP, which could be mediated by coping difficulties often present in personality 
disorders[264], but also by the fact that cognitive impairment is overrepresented in this 
group[129] among MS patients. The diagnosis group of organic and developmental disorders, 
which includes neuropsychiatric conditions considered to be secondary to an organic disease, 
also increased the HR for DP substantially. This group is heterogeneous and could for 
example reflect the disabling effects of conditions associated with latter stages of MS 
mentioned in section 1.2.6. 
Among the medications, antipsychotics were associated with the highest HR for DP, 
reflecting the serious nature of the conditions often treated with this class of drugs, namely 
bipolar disease and psychotic disorders. Additionally, the side effect profile of these 
medications, including various anticholinergic effects and extrapyramidal symptoms, could 
be especially unwanted in MS patients, and a causal contributing effect cannot be ruled out. 
This should also be considered regarding the elevated risk for MS patients treated with 
benzodiazepines. 
These results expand the existing knowledge on the synergistic effect of MS and psychiatric 
comorbidity on risk for DP, and suggest future research directions targeting depression, 
anxiety, and personality disorders to decrease individual and societal costs of DP. 
5.2.3 Disability pension and association with prescriptions of psychiatric drugs 
Study II shows that there are differences in the risk for being prescribed psychiatric drugs 
between MS patients and controls in the years before and after being granted DP. The fact 
that MS patients had higher rates of SSRIs after DP compared to controls, and that the rates 
of benzodiazepines increased after DP in MS patients, could be interpreted as DP not having 
an alleviating effect on the mental health burden in MS patients. It could also be that DP in 
itself adds to psychiatric morbidity in MS patients. Since clinical disability data was not 
available for this study, we cannot say whether progression of disability is reflected in the 
results, leading to increased prescriptions of psychotropic drugs. 
Being granted DP does not seem to have a beneficial effect on MS patients’ mental health in 
this study. A non-significant decrease in risk for both SSRIs and sleeping agents was seen 
among those on DP since 1-2 years, but not among those on DP since 3-6 years, which could 
stand for a brief relief of psychiatric burden after DP which is not lasting. Conversely, the 
non-MS controls on DP had lower risks for SSRIs compared to those not yet on DP, with the 
risk actually decreasing the more years they had been on DP. Considering that a third of the 
non-MS controls had mental DP diagnoses, the fact that MS patients still had a comparatively 
higher relative risk for being prescribed SSRIs after DP is noteworthy. 
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The majority of non-MS controls in this study had mental or musculoskeletal DP diagnoses, 
of which the most common (depression, musculoskeletal pain) usually do not have a 
progressive course. Most MS patients will sooner or later enter a progressive phase of the 
disease which could perhaps explain the differences in SSRI and benzodiazepine prescription 
after DP seen here compared to non-MS DP controls. However, patients with progressive 
stages of MS have not been shown to have higher rates of depression than patients with 
RRMS; there are even some contrary results. There is the possibility that DP itself contributes 
to the psychiatric burden in MS.  
Taken together, these results show that the risk for being prescribed drugs for depression and 
anxiety do not decrease among MS patients after DP, and also that this relationship differs 
when compared to non-MS controls. The perceived role of DP as a relief for MS patients 
warrants further consideration. 
5.2.4 An elevated risk for attempted and completed suicide 
Study III replicates previous research findings regarding the elevated suicide risk among MS 
patients in the largest cohort to date. Furthermore, an elevated risk for attempted suicide is 
demonstrated. This study also showed that the inverse association between higher education 
and completed suicide, as seen in the comparison cohort, was not present in MS patients. This 
risk difference could be due to chance, as the absolute number of suicides among MS patients 
with >14 years of education was low (n=14), but could also suggest that consideration should 
be taken in monitoring suicide risk among MS patients with higher educational attainment, as 
they could be clinically perceived as low-risk patients. 
The elevated risk for attempted and complete suicide was constant regardless of decade of 
study entry, except for completed suicide in the 1990s. Considering the advancement of MS 
treatments during the last decades, this is somewhat unexpected. The risk for completed 
suicide was highest among newly diagnosed MS patients, and the risk for attempted suicide 
highest after >20 years of disease. This suggests that attention to signs of depression and/or 
suicidality is even more warranted in these groups. 
As the elevated risk for suicidality in MS patients should now be considered well established, 
future research should focus on exploring possible mediating factors such as clinical course, 
pharmacological treatment and response, psychiatric and somatic comorbidity, and socio-
economic characteristics. 
5.2.5 Association between IL-6, depression and exposure to adult violence 
The main finding of study IV is that depression and exposure to adulthood violence is 
associated with CSF expression of IL-6 in MS patients. Although levels of exposure to 
violence was low in this study, and comparisons to non-MS patients should be made with 
caution, this is theoretically supported by the existing literature on stressful events and 
changes in IL-6 regulation in non-MS subjects in both blood and CSF. There is also a 
possible connection with the established association between stressful life events and MS 
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exacerbations. The molecular basis, however, remains to be determined, but may include 
effects mediated by adaptive, innate and glucocorticoid responses[265].  
Importantly, IL-6 levels have been suggested to also increase sensitivity to stress, which 
theoretically could imply a central role in both activation and maintenance of a stress cycle. 
We do not know if or how exposure to interpersonal violence, especially of the low-grade 
type most common in this study, differs from other kinds of stress regarding these 
mechanisms.  
 
This is, to our knowledge, the first demonstration of an association between external adverse 
events and an immune marker in MS patients. This has previously been reported in 
psychiatric populations, such as patients with MDD[266], and in patients with somatic 
disorders such as rheumatoid arthritis[194] and migraine [267]. For MS patients, this could 
have potential implications. For example, informative biomarkers are warranted for 
diagnostic, prognostic or therapeutic purposes[268], and could also be used for treatment 
decisions[269]. If there is an association between external stressful events and immune 
system regulatory mechanisms as demonstrated in this study, it suggests that potential 
immune system biomarkers must be evaluated only when known interactions between 
psychiatric symptoms and stressful events are carefully considered in order not to bias their 
interpretation. 
 
The findings in this study suggest that areas of future research should include the relation 
between stressful events, inflammatory response, MS incidence and long term MS prognosis.  
 
5.3 ETHICAL CONSIDERATIONS 
The studies included in this thesis were all approved by the Regional Ethics Committee at 
Karolinska Institutet, approval no. 2007/1762-31, 2009/1917-32, 2010/466-32 (studies I and 
II), 2013/1156-31/5, 2013/1973-32 (study III) and 2012/352-31/4 (study IV). 
Studies based on administrative registers do not entail any individual effort from the subjects 
studied, but there are ethical issues considering the integrity of individual data, the 
conclusions that can be drawn from register data, and security and cost issues of data 
management (see Ludvigsson et al[270] for an extended discussion). Clinical registers such 
as the SMSreg, however, do require an informed consent for participation, and also warrants 
extra data collection registration for the purpose of health care quality control and/or research. 
The possible benefits of this should be weighed against the administrative cost and the 
individual efforts from the participating patients. 
In clinical studies, the cost-benefit ratio for the participating subjects must be considered 
carefully. In study IV in this thesis, MS patients gave informed consent to participate in a 
special appointment for a clinical interview and to complete a self-rating scale. Answering 
questions regarding past adverse events and psychiatric symptoms may in some cases elicit 
feelings of discomfort and psychological distress. All patients who were considered in need 
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of psychiatric follow-up, and consented to it, were referred to appropriate care. All patients 
were informed of the possibility of a follow-up telephone contact with the interviewing 
psychiatrist. The study was designed so that no extra lab tests or examinations were needed 
outside of ordinary clinical practice. A possible benefit for the participating patients was the 
identification and treatment initiation of psychiatric symptoms. 
 
5.4 GENERAL DISCUSSION AND FUTURE DIRECTIONS 
The studies in this thesis look at psychiatric comorbidity in MS patients from 
methodologically different angles; as an exposure, with DP or immunomarkers in CSF as 
outcomes, or as outcome compared to non-MS patients, or in relation to DP.  The question of 
MS and psychiatric comorbidity is complex, and this thesis has probably not helped 
simplifying the matter – with the possible exception that we may with even greater certainty 
state that psychiatric comorbidity is overrepresented among MS patients, and worsens the 
outcome for the patients in several pivotal ways. 
This thesis starts with an attempt to review the current literature on psychiatric comorbidity in 
MS, and it soon becomes utterly clear that important pieces of the puzzle are missing. A 
major problem is that both MS and psychiatric disorders are syndromes with a great 
heterogeneity in their clinical presentation, and not etiological diagnoses. When studying 
these conditions, we are not sure that any two patients share the same underlying pathology, 
only that their presenting symptoms are (somewhat) similar. Furthermore, we are not helped 
by the fact that some of the most common and important symptoms in MS patients that 
mediate psychological distress, such as fatigue, pain, and sleeping problems, lack operational 
criteria. 
In the last few years, a number of interesting studies based on Scandinavian registers have 
looked retrospectively at MS patients in the years before diagnosis. Looking at Norwegian 
conscription data, men who would later develop RRMS or PPMS scored significantly lower 
on IQ tests than comparators – and for PPMS patients, differences were significant up to 20 
years before first diagnosis[80]. In a Swedish conscription cohort, men with MS had lower 
physical working capacity in adolescence - but this study did not show significant differences 
in cognitive function and stress resilience scores between cases and controls[271]. Moreover, 
patients in the SMSreg had significantly higher rates of both sickness absence and DP up to 
15 years before MS diagnosis compared to matched controls[272]. 
These results highlight the question if there is a psychiatric phenotype among MS patients 
before diagnosis, with or without presence of other symptoms. Johansson et al[53] 
demonstrated that genetic liability could not explain the strong positive association between 
MS on one hand, and MDD and type I bipolar disorder on the other. However, the underlying 
factors for psychiatric disorders may be more complex than observation of distinct 
categorical entities may reveal. Given the high rates of comorbidity observed in psychiatric 
patients, and growing evidence that current psychiatric nosology may not adequately explain 
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occurrence and co-occurrence of psychiatric morbidity, Caspi et al[273] examined the notion 
of a “p factor”, i.e. an underlying dimension to the risk of developing all forms of common 
psychopathology, in a well-characterized longitudinal cohort. Higher scores on this 
dimension were associated with greater life impairment, worse developmental histories, and 
more compromised brain function in early life. It would be very interesting to see whether 
such a model would be applicable also to MS patients regarding occurrence of psychiatric 
symptoms, but also whether such an underlying factor would somehow be related to the 
occurrence and outcomes of MS in itself. 
The importance of functional coping styles has been well established in later years of MS 
research, and would be interesting to explore as a mediator for all outcomes in this thesis, 
diverse as they may be. Coping mechanisms in MS patients have been linked to such varied 
outcomes as depression[274], fatigue[275], unemployment[276] and suicidal ideation[75]. 
Identifying MS patients with non-functional coping styles seems to be a priority. However, 
taking into account the results from study IV in this thesis, and in line with the reasoning 
above, coping style as a personality trait should perhaps also be explored as risk factor for 
developing/worsening MS. 
The role of stress as a risk factor for MS has been explored historically as described in section 
1.2.7. What if persons who react non-functionally to adverse events pre-MS diagnosis are at 
greater risk for developing changes in the immune response after such events, and this could 
be a contributing factor to development of MS? And could an innate predisposition for non-
functional coping also mediate the high prevalence of some types of psychiatric comorbidity 
in MS, and hence work as a confounder? The only way to thoroughly answer this research 
question would be through case-control studies using cohorts where coping styles have been 
examined in a large number of subjects, preferably before the typical age of MS onset. If MS 
patients have different coping styles than other persons with disability or chronic diseases, 
this might also explain the lack of beneficial effect of DP on psychiatric morbidity seen in 
study II. This reasoning is summarized in Figure 5. 
In summary, future research on risk factors for, and consequences of, psychiatric comorbidity 
in MS faces several challenges. Current nosological psychiatric classification may not be 
adequate for describing the psychiatric symptoms in MS, which poses a real problem since 
register based research often depend on diagnoses. Clinical registers such as the SMSreg and 
its equivalents from other countries may insure the collection of clinical parameters such as 
disability data, rating scales and cognitive screening tests. Functional outcomes of value both 
for the patient and for society must be identified and evaluated further, and sickness absence 
and DP data could be considered strong candidates. Also, risk factor identification for MS, 
including possible connections to premorbid personality or functioning, depend on case-
control studies, where large population scale studies and register research could prove to be 
of further use. It is not enough to state a high risk for detrimental outcomes such as DP or 
suicide among MS patients; further identification of risk factors is warranted with the purpose 
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of constructing adequate clinical screening tools and, ultimately, clinical measures, to prevent 
them. 
 
 
Figure 5. A conceptional model of findings in this thesis, with the proposed addition of non-
functional coping as a mediating factor. 
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6 CONCLUSIONS 
 
We conclude that there is an elevated risk among MS patients for psychiatric comorbidity 
including attempted and completed suicide, that the presence of psychiatric comorbidity 
increases the risk for disability pension, that disability pension may not be associated with a 
relief of psychiatric burden as in non-MS patients, and that exposure to violence in adult life 
and depression is associated with changes in the immune system among MS patients. 
Proposed targets for future research include early detection and treatment of various kinds of 
psychiatric comorbidity as well as identification of risk factors, as well as measures for 
staying in the labor market. The association between life adversity and neuroinflammation 
should be further explored. 
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